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Abstract 
 
KtrAB is a potassium transporter, present widely among prokaryotes, which is 
essential for the adaptation to osmotic stress and resistance to high salinity, among 
other properties. This transporter is composed of two polypeptides: a membrane 
protein, KtrB, which facilitates ion passage, and a cytosolic protein, KtrA, that has 
regulatory functions and is an RCK domain (regulates conductance of potassium). 
Unlike the very well known potassium channels, the mechanisms by which this 
transporter regulates and enables ion passage are not well established and so, it is 
critical to obtain high resolution structures that can help understand these aspects. 
The aim of this project was to obtain a KtrA mutant that makes it more stable 
and that can help improve the diffraction quality of protein crystals resulting in higher 
resolution structures. In order to do so, several residues in the C-terminal domain of 
KtrA were mutated, both in the core and at the surface of the domain, introducing 
amino acids that could potentially stabilize the protein. The mutants that were tolerated 
were purified and tested in a thermal shift assay, which evaluated the melting 
temperature of each mutant. All mutants tested resulted in a stabilization of the protein 
structure and were combined to further improve stability. Some of the properties of final 
combination mutant, named KtrA CysLHDN, were evaluated. In particular, it was 
verified that the mutant assembles with the KtrB membrane protein and that it forms 
protein crystals that diffract better than the wild-type protein. As a result, a crystal 
structure of KtrA CysLHDN bound to ATP was obtained at 2.8 Å. 
The recent discovery of a new ligand that binds to the C-terminal domain of 
KtrA, c-di-AMP, led to a new aim in the project.  This ligand was tested with the native       
KtrA and some mutants in thermal shift and ITC assays. It was possible to show that 
the ligand not only binds to KtrA, but also stabilizes the protein. This stabilization 
occurs when KtrA is bound to ADP but not when KtrA is bound to ATP. The ITC 
allowed the determination of a dissociation constant of 12 µM and a stoichiometry of 1 
c-di-AMP molecule per KtrA dimer. ITC measurements confirmed the thermal shift 
results and c-di-AMP appears to not bind to the KtrA-ATP complex. 
 
Key-words: K+ transporter; KtrAB; KtrA; c-di-AMP; crystal structures; RCK 
domain; protein stability.  
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Resumo 
O KtrAB é um transportador de potássio, amplamente presente em procariotas, 
que é essencial para a adaptação ao stress osmótico e para a resistência a salinidade 
elevada, entre outras propriedades. Este transportador é composto por dois 
polipeptídeos: uma proteína de membrana, KtrB, que facilita a passagem de iões, e 
uma proteína citosólica, KtrA, que tem funções reguladoras e é um domínio RCK 
(regula a condutância de potássio). 
Contrariamente aos conhecidos canais de potássio, os mecanismos através 
dos quais este transportador regula e permite a passagem de iões ainda não estão 
bem definidos e portanto, é crucial obter estruturas com resolução elevada que 
permitam entender estes aspectos. 
O objectivo deste projecto foi obter um mutante de KtrA que a torne mais 
estável e ajude a melhorar a qualidade de difracção dos cristais proteicos de modo a 
obter estruturas com resolução mais elevada. Neste sentido, foram mutados resíduos 
no domínio C-terminal de KtrA, tanto no núcleo como à superfície, introduzindo 
aminoácidos que poderiam eventualmente estabilizar a proteína. Os mutantes 
tolerados foram purificados e testados num ensaio de variação térmica que avaliou a 
temperatura de desnaturação de cada mutante. Todos os mutantes testados 
contribuíram para uma estabilização da estrutura proteica e foram combinados de 
forma a aumentar ainda mais a estabilidade. Algumas propriedades do mutante 
resultante da combinação final, denominado KtrA CysLHDN, foram avaliadas. 
Particularmente verificou-se que o mutante se liga à proteína de membrana KtrB e 
forma cristais proteicos que difractam melhor do que a proteína nativa. 
Consequentemente, uma estrutura cristalográfica de KtrA CysLHDN ligada a ATP foi 
obtida a 2.8 Å. 
A descoberta recente de um novo ligando que se liga ao domínio C-terminal de 
KtrA, c-di-AMP, levou a um novo objectivo no projecto. Este ligando foi testado com 
KtrA nativa e alguns mutantes em ensaios de variação térmica e ITC. Foi possível 
demonstrar que este ligando não só se liga a KtrA, como também estabiliza a proteína. 
Esta estabilização ocorre quando KtrA está ligada a ADP mas não quando KtrA está 
ligada a ATP. O ITC permitiu a determinação de uma constante de dissociação de 12 
µM e uma estequiometria de 1 molécula de c-di-AMP por dímero de KtrA. O ITC 
confirmou os resultados da variação térmica e c-di-AMP parece não se ligar ao 
complexo KtrA-ATP. 
Palavras-chave: Transportador de K+; KtrAB; KtrA; c-di-AMP; estruturas 
cristalográficas; domínio RCK; estabilidade proteica.  
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Introduction 
 
Physiological role of the potassium (K+) ion 
 
Potassium (K+) is the major inorganic cation present in the cell cytoplasm of 
both prokaryotic and eukaryotic cells, being an essential element to all living organisms 
[1]. In bacteria, K+ concentration in the cytosol ranges between 300 and 500 mM [2], 
and the accumulation of this particular ion is attributed to its compatibility with water 
and proteins [1]. 
K+ contributes to the electrical neutralization of anionic groups in 
macromolecules, while also playing a determinant role in several biological processes, 
such as osmoregulation [2], maintaining intracellular pH [3], and establishing the 
transmembrane electrical potential [4]. 
In regard to osmoregulation, K+ levels inside the cell are determined by the 
osmolarity of the external medium, rising with high osmolarity, and decreasing when 
the osmolarity lowers [2, 5], thereby maintaining the turgor pressure stable. Also, the 
accumulation of potassium in situations of osmotic stress leads to the expression and 
stimulation of specific proteins like ProU [6] and BetP [7], transport systems for betaine, 
a compound that acts as an osmoprotectant. 
On the other hand, solute transport and cell motility in prokaryotes are driven by 
a transmembrane electrochemical potential of protons known as the protonmotive 
force. This force has two components: the membrane potential and the pH gradient [3]. 
The potassium ion flux regulates these two components, since it has been shown that 
K+ uptake leads to a depolarization of the membrane (reduction of a membrane 
potential to a less negative value due to an increase in positive charges inside the cell) 
[4], which in turn translates in an increase of the internal pH of the bacteria, achieved 
by partial exchange of K+ by H+ [8]. Potassium ions also seem to play a role in protein 
synthesis by binding close to the active centre of the 23S-rRNA from the ribosome, 
although it is not yet clear if this binding is essential for the catalytic function of the 
ribosome [9].  
In order to regulate these vital potassium fluxes and adapt rapidly to changes in 
the environment, prokaryotes use several channels, transporters and pumps since the 
cell membrane is virtually impermeable to K+. 
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 K+ uptake systems 
 
Potassium uptake in animal cells is regulated mainly by the Na+/K+-ATPase 
[10]. However, in bacteria, fungi and plants it is mediated largely by two specific 
families of transporters, namely Trk/Ktr/HKT and HAK/Kup/KT, that don’t exist in animal 
cells [1]. The Trk/Ktr/HKT family is present almost ubiquitously in plants, fungi and 
bacteria and is comprised by a large variety of transporters including H+-K+ symporters, 
Na+-K+ symporters and Na+ transporters. On the other hand, the HAK/Kup/KT family is 
present in organisms adapted to low potassium conditions [11] and is composed mainly 
of K+ transporters [1], however this family won’t be discussed further here. 
The Trk/Ktr/HKT superfamily is divided into different groups: the Transport of K+ 
in fungi and bacteria (Trk), the K+ transporter in bacteria (Ktr) and the High-affinity K+ 
transporter in plants (HKT). 
Importantly, this superfamily is evolutionary related to small two transmembrane 
potassium channels such as the KcsA and MthK potassium channels [12]. 
 
Trk and Ktr systems in bacteria 
 
Trk and Ktr are multimeric complexes formed by an ion-conducting 
transmembrane subunit, which can be TrkH, G or I (in Trk systems) and KtrB or D (in 
Ktr systems), and a regulatory subunit: TrkA or E and KtrA, C or E respectively [1].  
The Trk subfamily has been extensively studied in Escherichia coli, since this 
organism contains not only the ion conducting TrkH subunit, but also the TrkG subunit 
in the K12 strain [13]. These two subunits have been shown to establish multimeric 
functional transporters in association with the regulatory cytoplasmatic subunit TrkA 
[14]. Several studies have also demonstrated that TrkA is essential for high-level Trk 
activity since mutating the trkA gene abolishes K+ transport [15]. 
TrkA subunits contain two similar domains that are RCK domains. RCK 
(regulating the conductance of K+) domains modulate the function of some eukaryotic 
and prokaryotic potassium channels and transporters that are essential to regulation of 
K+ uptake in the cell. These domains can be classified into two types based on their 
cognate ligands: one type consists in the bacterial RCK domains that possess a 
conserved GXGXXG motif (Rossman fold) that binds to nucleotides, and is sometimes 
known as a KTN (K+ transport, nucleotide-binding) domain [16]. The other is composed 
of the bacterial and mammalian RCK domains that lack this motif and bind ions such as 
Ca2+ [17, 18]. 
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Each of the TrkH domains has a nucleotide-binding site that has been shown to 
bind NAD+/NADH. It has been proposed that this allows the transporter to be 
responsive to the redox state of the cell [19]. One other regulating subunit identified in 
E.coli is TrkE that, unlike TrkA, confers ATP-responsiveness to the transporter when in 
complex with TrkG or H creating an ATP-dependent stimulation of K+ transport [20]. 
Overall the Trk system in E.coli is a constitutive, low-affinity K+ transport 
system, regulated by the protonmotive force and ATP. It displays an estimated affinity 
of 1mM (KM) for K
+ and has been proposed to perform symport of 1 H+ with 1 K+, with 
ATP acting as a regulator [21]. This symport with H+ is particularly interesting when it 
comes to halophilic bacteria such as Halomonas elongata that are thought to rely on 
Trk systems, mainly TrkI and TrkA, for potassium transport in order to avoid Na+ intake 
in saline environments and therefore diminish salt stress [22]. 
The Ktr subfamily has been well characterized in the cyanobacterium 
Synechocystis and in Bacillus subtilis. In Synechocystis, there is only one KtrB ion-
conducting subunit, previously known as NtpJ [23]. This subunit forms a complex with 
two regulatory subunits, KtrA and KtrE, that is essential for potassium uptake and 
adaptation to hyperosmotic shock in this bacteria [24]. KtrA is similar to TrkA from the 
Trk system but has only one RCK domain. On the other hand KtrE shows similarities to 
glycosyl transferases. 
In B.subtilis, there are two Ktr transport systems, KtrAB and KtrCD [25]. These 
systems are required for adaptation to hyperosmolarity. They differ in affinity for 
potassium, KtrAB has a Kd for K
+ of 1 mM as opposed to the 10 mM in KtrCD. KtrB has 
been shown to form homodimers [26] that assemble with an octameric ring comprised 
of four KtrA dimers to form a functional complex. KtrA binds ATP, displaying eight 
binding sites in the octameric ring [27]. Binding of these ligands results in 
conformational changes of the complex KtrAB that regulate potassium uptake. 
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Structural organization of Trk and Ktr systems 
 
Typically, the transmembrane subunit of Ktr in bacteria is composed of four 
M1PM2 (transmembrane helix, pore, transmembrane helix) repeats, whereas the Trk 
transmembrane subunit has two additional transmembrane segments (TM1 and TM2) 
before the first M1PM2 repeat as shown in Figure 1. In each repeat, M1 and M2 are 
helices connected by the P loop, a protein region, which is composed of a pore-helix 
spanning part of the membrane, followed by an extended loop [28]. These MPM 
domains are thought to have evolved from a common potassium channel ancestor with 
a MPM protomer through a process of gene duplication and fusion [1]. Since K+ 
channels have the same subunit fold and are tetramers, it has been proposed that the 
structures of Trk/Ktr/HKT membrane proteins resemble those of K+ channels [29]. 
 Several functional studies supported this proposal, namely by showing that a 
mutation in a conserved glycine residue in the P loop changes the ion selectivity of the 
Trk/Ktr/HKT proteins in bacteria [30]. However, unlike K+ channels, where the P 
segment contains a very conserved signature sequence (TVGYG) that forms the 
selectivity filter responsible for the coordination with the potassium ion, in Trk/Ktr/HKT 
proteins the equivalent sequence is not so strictly conserved. 
 
 
 
 
 
 
 
Fig.1- Scheme depicting the structural architectures of Trk and Ktr proteins (bottom) and of their putative potassium 
channel ancestor (top). Adapted from Corratge-Faillie 2010. 
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TrkAH structure 
 
Recently, the structures of TrkH alone and of TrkH in complex with TrkA have 
been solved [16, 31]. TrkH was shown to be a dimer, in which each subunit is 
composed of five regions (D0 to D4) and contains one K+ ion. D0 corresponds to the 
TM1-TM2 segment previously discussed and D1 to D4 are MPM repeats. The dimer 
interface between the two subunits is formed by helices from both D3 and D4. 
 D1 to D4 assemble in a pseudo-fourfold symmetry axis that creates an ion 
permeation pathway with an hourglass shape. This ion permeation pathway is 
contained in each TrkH subunit and has two important features: a selectivity filter and 
an intramembrane loop. The selectivity filter is part of the pore loop; it is encompassed 
by the four pore helices, in a similar arrangement as seen for K+ channels, and 
includes a conserved glycine residue as expected (see Figure 2). However, the 
selectivity filter of TrkH has a wider opening on the extracellular side, compared to 
those of K+ channels, and a shorter constricted region for potassium coordination [16]. 
 
 
 
 
 
 
  
 
 
 
The intramembrane loop acts as a barrier for K+ permeation and is positioned 
close to the selectivity filter. This barrier is formed by two elements: Arginine 468 from 
the second transmembrane segment of D4, conserved in all bacterial Trk/Ktr/HKT 
proteins, and an intramembrane circular loop that is present in TrkH, TrkG and KtrB 
and is rich in glycine and other small residues such as serine and alanine, which are 
well conserved across different sequences (see Figure 2) [16]. These two elements 
form a narrow constriction that needs to widen in order to allow K+ passage, possibly 
acting as a gate, a feature that hasn’t been observed in the structure of any potassium 
channels to date. 
 
Fig. 2 - TrkH pore. a) sequence alignment of the pore helix (box) and selectivity filter (underlined) of each TrkH 
repeat and of the K
+
 channel KcsA, showing the conserved glycine in red. b) Surface representation of the ion 
permeation pathway hourglass shape in one TrkH subunit: the selectivity filter is colored yellow and the 
intramembrane loop colored magenta. Adapted from Cao 2011. 
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TrkH assembles in a complex with TrkA, so that a TrkH dimer interacts with a 
ring formed by four TrkA protomers. Each TrkH monomer interacts with TrkA through a 
cytosolic loop in D3 that is directly connected to the intramembrane loop [31].This 
interaction is another difference when compared to K+ channels that are regulated by 
RCK domains, since the RCK domain is encoded in the same polypeptide so that the 
membrane protein and the regulatory ring in the cytoplasm are covalently bound. 
The TrkA protomer contains two tandem RCK domains (RCK1 and RCK2), and 
the ring has a total of eight RCK domains with two GXGXXG nucleotide-binding site 
motifs (Rossman fold) in each RCK domain. The tetramer of TrkA protomers shows 
two different subunit interfaces: one between the N-terminal lobes of RCK1 (N1-N1) 
and another between the N-terminal lobes of RCK2 (N2-N2) as shown in Figure 3. This 
organization is different from the one observed for K+ channels such as BK and MthK, 
where the gating ring contains four identical N1-N2 interfaces. 
The structure obtained by the same authors for TrkA alone in solution shows a 
substantial conformational change compared to the complex structure. In this second 
structure, the N2-N2 interfaces rotate and slide past each other, converting TrKA from 
a planar to a twisted conformation. This conformational change may be regulated by 
nucleotide-binding and act as a mechanism for activating the TrkH-TrkA complex. Cao 
and colleagues propose a model in which binding of ADP to TrKA results in a closed 
state corresponding to the planar structure obtained for the TrkH-TrkA complex, where 
the ion permeation pathway is blocked by the intramembrane loop. Upon exchange of 
ADP for ATP, the gating ring would adopt a twisted conformation where the tretamer 
could lead to movement of the loop out of the pore, freeing the ion permeation pathway 
and opening the channel [31]. This model is supported by studies that show that ion 
flux through the complex is upregulated by ATP and downregulated by ADP [31], but 
higher resolution structures of the complex are still needed in order to confirm the 
hypothesis. 
 
 
 
 
 
 
 Fig.3 - Structure of the TrKH-TrkA complex and TrkA alone. a) Structure of the complex formed by the TrkH dimer (light 
blue and teal) and the TrkA tetramer (dark blue and purple). b) Structure of the TrkA ring  with the N1-N2 protomer 
highlighted. c) Structure representation of TrkA in complex with TrkH and alone, showing the 2 different conformations: 
planar on the left and twisted on the right. Adapted from Cao 2013. 
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KtrAB Structure 
KtrAB is a novel high-affinity Na+-dependent K+ uptake system found in Vibrio 
alginolyticus. This constitutively expressed system was identified by Nakamura and 
colleagues as the product of two adjacent genes that encode for: KtrB, previously 
known as NtpJ, of predicted molecular mass of 45,623 Da, and KtrA, of predicted 
molecular mass of 23,804 Da [23]. 
 The system is formed by the assembly of a complex between a homodimer of 
the membrane protein KtrB and an octamer of the cytosolic protein KtrA (see Figure 4) 
[27]. In Staphylococcus aureus, KtrAB has already been shown to play a determinant 
role in the regulation of several biological processes such as pH regulation, growth in 
low K+ conditions, resistance to osmotic stress, regulation of the membrane potential 
and antimicrobial resistance [32]. 
The crystal structure of KtrAB with KtrA bound to ATP was recently solved at 
3.5 Å [33], showing the expected homodimeric KtrB bound to the cytoplasmic 
octameric ring of KtrA. As previously stated, KtrB is an integral membrane protein 
composed by four repeats of the M1PM2 structural motif (D1 to D4), lacking the N-
terminal TM1-TM2 helices present in Trk. The P loop region includes the pore (P) helix 
and the selectivity filter sequence. Just like in TrkH, below the selectivity filter there is 
an intramembrane loop in repeat D3 composed mainly of glycine, alanine and serine 
residues [33]. Together with a highly conserved arginine residue (R417), this loop 
forms a structure that blocks access between the selectivity filter and the cytoplasmic 
pore, most likely acting as a gate [34]. 
The major difference between KtrB and TrkH lies in the C-terminus. TrkH has a 
shorter C-terminus that does not establish any contacts whereas KtrB has a long C-
terminus that runs from one subunit to the other, forming a lateral contact with KtrA and 
entering the pore of the neighbouring subunit, finishing just below the intramembrane 
loop [33]. Also, in KtrB a highly conserved C-terminal glycine (G445) is positioned close 
to the intramembrane loop so that its C-terminal carboxylate group interacts with the 
side chain of a lysine that is part of the intramembrane loop and is conserved in both 
KtrB (K315) and TrkH (K357). This C-terminal glycine does not exist in Trk proteins, but 
appears to be replaced by a glutamate (E470) in TrkH that also interacts with the lysine 
(K357). The glycine carboxylate by itself does not appear to have a substancial effect 
in the regulation of the transporter has shown by truncation studies [33]. However, 
removal of the last four residues of the C-terminus of KtrB results in a non-functional 
transporter, since KtrB loses its ability to form a complex with KtrA [33]; these residues 
also appear to be important for the stability of the KtrB dimer [26]. 
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The KtrB dimer sits directly on the face of the KtrA ring, establishing two types 
of contacts with it through cytoplasmic loops: a lateral contact and a tip contact. The 
lateral contact is established by a section of the KtrB C-terminus which runs along the 
homodimer interacting with the neighbouring KtrB subunit and the KtrA ring. The tip 
contact occurs at the apexes of the cytoplasmatic face of KtrB where cytoplasmic loops 
connecting D1 to D2 interact with two opposing KtrA subunits as illustrated in Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
Fig.5 - Top view of KtrAB with cartoon representation KtrB domains: D1 (red), D2 (yellow), D3 (orange) and D4 (blue). 
KtrA octameric ring is show as a grey surface and the lateral and tip contacts are pointed out. 
 
 
 
Fig.4 - KtrAB transporter.Cartoon of the KtrAB transporter with KtrB subunits shown in orange and light blue; KtrA 
subunits are in dark blue and red; ATP is shown asyellow spheres and K
+
 as magenta spheres; cell membrane is shown 
as a pale yellow rectangle (left). Cartoon of one subunit of KtrB showing the pore and pointing out the selecitivy filter 
and the intramembrane loop with K
+
 as a magenta sphere (right). Adapted from Vieira-Pires 2013. 
FCUP 
Biochemical studies of a membrane protein: The KtrAB ion transporter 
9 
 
KtrA Structure  
 
A C-terminal truncated KtrA crystal structure was first solved bound to NADH by 
Roosild and colleagues in 2002 at 2.85 Å resolution [19]. This structure showed a 
homodimer assembly with NADH bound to the N-terminal and it was proposed that four 
RCK domains (a dimer of dimers) would bind to KtrB and regulate the transporter. 
However, later on a structure at 2.20 Å resolution was determined by Albright and 
colleagues [27], displaying the homodimers organized in an octameric ring with a 
diamond shape conformation, similar to the one observed for the MthK potassium 
channel. The NADH ligands are bound to the N-terminal facing the hole of the ring 
whereas the C-terminals of the dimers are facing outward. Moreover, it was shown that 
the KtrA truncate could also bind ATP and ADP, even more tightly than NADH or 
NAD+, raising the possibility that these nucleotides have a functional role in the 
regulation of KtrAB. 
 Crystal structures of the truncated KtrA obtained in the presence of the different 
ligands revealed that the octameric ring is capable of adopting three different 
conformations: a diamond, previously seen with NADH and also seen for ATP and 
ADP; a square when bound to ATP and NADH and a rectangle, observed with NADH, 
as illustrated in Figure 6. This finding is interesting in the measure that RCK domains 
regulate ion transporters by changing conformation upon ligand binding and, in light of 
these results, the same conformation can be achieved by different ligands. However, 
this might be explained by a different behaviour of the ring in the absence of KtrB or by 
the lack of the C-terminus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.6 - Surface representations of the three conformations adopted by the truncated KtrA. Subunits are shown 
alternately in blue and red and ligands are shown in green. Adapted from Albright 2006. 
FCUP 
Biochemical studies of a membrane protein: The KtrAB ion transporter 
10 
 
 
Recently, crystal structures for the native full-length KtrA from Bacillus subtilis 
bound to both ATP and ADP were solved at 3.2 Å and 2.9 Å resolution, respectively. 
These new structures clearly show a different ring conformation for each ligand: a   
two-fold diamond shape conformation with ADP and a four-fold squared shape 
conformation with ATP [33] (see Figure 7). The conformation of the isolated KtrA ring 
with ATP is very similar to the conformation of the ATP bound KtrA ring in the KtrAB 
complex. This indicates that, unlike the truncated form where ligand binding is not 
coupled to ring conformation, in the full-length KtrA the binding of either ATP or ADP 
determines the conformation of the ring. These results reinforce the hypothesis of an 
essential role played by the C-terminus of KtrA in the conformation adopted by the KtrA 
octameric ring upon ligand binding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig.7 - Structures of the full length KtrA bound to ATP or ADP. Alternating subunits are shown in red and blue. 
Adapted from Vieira-Pires 2013. 
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KtrAB Activity 
 
Uptake assays for KtrAB bound to ATP and ADP using rubidium labelled 
radioactively have shown that ATP is an activator of KtrAB [33]. 
Two possible activation mechanisms have been proposed, assuming the 
intramembrane loop of KtrB as a gate. The first model assumes that contraction or 
expansion of the KtrA ring occurs along the diagonal defined by the lateral contacts, 
since there is a direct connection between the KtrB C-terminus that interacts with KtrA 
and the intramembrane loop. The second model assumes that the contraction or 
expansion occurs along the tip contacts, where the D1-D2 loop would function as a 
gate controlled by KtrA and the intramembrane loop activated by another stimulus [33]. 
Both models have opposing evidences against them and so, to get a better 
understanding about the regulation of KtrAB, it is crucial to obtain structures with higher 
resolution. These structures would contribute to the definition of a mechanism that 
explains how the transporter is regulated. 
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Physiological role of cyclic nucleotides 
 
Nucleotides are essential components of all living organisms, since they are 
needed to synthesise DNA and RNA and are used as an energy source [35, 36]. These 
molecules have also been shown to act as secondary messengers, by regulating 
signalling pathways that affect various aspects of eukaryotic and bacterial cells, as well 
as archaea. Among nucleotides, the first second messenger to be described was cyclic 
adenosine monophosphate (cAMP), which regulates several biological processes in 
eukaryotes, from metabolism to memory formation and immunity, functioning as a 
major gene expression regulator. In bacteria this molecule plays a role in carbon 
catabolite repression and virulence control, among other processes. It influences these 
processes by binding to certain proteins and changing their conformation [37]. 
One other nucleotide that as emerged as an important second messenger is 
cyclic diguanosine monophosphate (c-di-GMP), a cyclic dinucleotide obtained from the 
condensation of 2 molecules of GTP by the action of diguanylyl cyclases. Like cAMP, 
c-di-GMP also binds allosterically to receptor proteins, thus regulating several 
signalling pathways, namely the switch from a motile to a biofilm lifestyle in bacteria 
[38]. 
 
Cyclic di-AMP 
 
Very recently, another cyclic dinucleotide is beginning to be characterized due 
to its relevance in bacteria. This nucleotide is cyclic diadenosine monophosphate (c-di-
AMP) and, after c-di-GMP, is the second cyclic dinucleotide shown to be produced by 
bacteria. Although not a lot is known about this last molecule, all evidence so far 
indicates that these two cyclic dinucleotides regulate different processes [36]. 
c-di-AMP was first found in the cytosol of Listeria monocytogenes by Woodward 
and colleagues, and shown as a secreted molecule of multidrug efflux pumps (MDRs), 
which leads to IFN-β production [39]. Since then, it has also been found in other 
bacteria such as Streptococcus pyogenes [40], Bacillus subtilis [41], Chlamydia 
trachomatis [42] and Staphylococcus aureus [43]. This molecule is synthesised trough 
the condensation of 2 ATP molecules by a diadenylyl cyclase (DAC) domain present in 
DisA proteins and degraded to 5'- Phosphoadenylyl-(3'−>5')-adenosine (pApA) by 
GdpP, a phosphodiesterase (PDE), both widely distributed among bacteria [36]. 
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As previously stated, the manner in which c-di-AMP regulates signalling 
pathways is still mostly unknown but since it is produced by DisA, a protein that scans 
the integrity of the DNA for double-stranded breaks, it has been suggested that it could 
play a role in signalling DNA damage [44]. In the last couple of years, c-di-AMP has 
been associated with several cellular functions: an increase in acid resistance [45, 46], 
as well as sporulation regulation related to DNA damage [41] in Bacillus subtilis, 
regulation of fatty acid synthesis in Mycobacterium smegmatis [47], the growth of 
Staphylococcus aureus in low-potassium conditions [35] and cell wall homeostasis in 
several species [43, 48].  
Like other signalling nucleotides, c-di-AMP acts by binding to specific receptor 
proteins and allosterically altering their activity, thereby regulating cellular pathways. 
Lately, several receptors have been found: the transcription factor cyclic di-AMP 
receptor regulator (DarR) from de TetR (tetracycline resistant) family in Mycobacterium 
smegmatis [47], the histidine kinase KdpD, the PII-like signal transduction protein PstA 
in Staphylococcus aureus [35] and also the RCK domain proteins KtrA and cation 
antiporter A (CpaA) in Staphylococcus aureus [35]. 
In the case of KtrA, it was shown with a ligand assay that c-di-AMP binds 
specifically to the C-terminus of this RCK domain from S.aureus [35]. This finding is 
particularly interesting when coupled with the previous discoveries in the KtrA from B. 
Subtilis, which indicate that the C-terminus plays a role in the type of conformation 
adopted by the octameric ring; ligand binding to the C-terminal domain of KtrA would 
contribute to the mechanism of regulation of the transporter. Therefore it is relevant to 
understand if c-di-AMP also binds to the KtrA from B.subtilis and if so, try to determine 
the nature of the binding. Moreover it would also be interesting to try to discern what 
possibly role it could play in the regulation of the activity of the KtrAB transporter. 
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Goals and aims 
 
 Potassium transporters, particularly the Trk and Ktr systems, play an 
essential role in the regulation of vital cellular processes in prokaryotes by mediating K+ 
uptake. Therefore understanding how these transporters are regulated is determinant 
to improve our knowledge of these organisms. In this sense, crystal structures provide 
a reliable source of information regarding the 3D structural organization of proteins and 
are, as such, important tools in the process of proposing mechanisms of function and 
regulation of protein systems. 
In the particular case of the K+ uptake system KtrAB, structures have already 
been determined for both the KtrAB complex and the RCK domain KtrA bound to its 
known ligands. These structures, along with biochemical assays, have been used to 
propose regulation mechanisms for this system. However, there still remain 
contradictory evidence and ideas against these proposals and higher resolution 
structures are needed in order to fully define these mechanisms. 
One aim of this work was to develop KtrA C-terminal mutants that were able to 
improve the stability of the protein and the crystal lattice. Crystallization conditions for 
the best mutants would then be defined to possibly determine higher resolution 
structures for KtrA and KtrAB. 
From previous studies, it has become clear that the C-terminal of KtrA plays a 
role in the conformation adopted by the octameric ring of the isolated protein and of the 
KtrAB complex. The recent discovery of a new ligand that binds specifically to the      
C-terminal of KtrA from S.aureus, cyclic di-AMP, presents a unique opportunity to 
determine if this nucleotide has a role in the regulation of the KtrA conformation and 
consequently of the whole system. Therefore, another aim of this work was to 
determine if c-di-AMP binds to the KtrA from B.subtilis and to characterize the binding 
properties. 
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Results and Discussion 
 
Development of KtrA C-terminal mutants 
 
The diffraction pattern of KtrAB is anisotropic [33]; it extends to 3.3 Å along the 
best direction and at close to 4 Å in the other two directions. Analysis of the crystal 
structure of KtrAB shows that the weak diffraction corresponds to the protein-protein 
contacts that are formed by the C-terminal domains of the KtrA rings from neighbouring 
channels (see Figure 8). A detailed analysis of the KtrA C-terminal domain reveals the 
presence of disordered regions and cavities in the core of the domain. These structural 
“defects” probably weaken the protein-protein contacts, impairing the formation of 
better diffracting crystals. 
 
 
 
 
 
 
 
 
Fig.8 - Representation of the crystal lattice of KtrAB. Top view cartoon structure highlighting the contacts between two 
KtrAB transporters in the same crystal. The KtrB dimer is shown in orange with the potassium ion colored magenta. The 
KtrA octameric ring is shown at the bottom with the N-terminals colored white and the C-terminals colored alternately 
dark blue and red to show the dimers. 
 
In order to improve the crystal lattice and therefore increase the quality of 
crystals obtained for this transporter, KtrA C-terminal mutants were developed by 
applying two different strategies: a cavity filling strategy and an exposed surface 
strategy.  
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Cavity Filling 
 
The cavity filling strategy consists in mutating some key residues in order to fill 
cavities detected in the crystal structures previously obtained for KtrA. These cavities 
are present in the core of the C-terminal domain of KtrA and, by introducing a residue 
with similar chemical character but bulkier side-chain, it can fill the cavity, make the    
C-lobe more compact and therefore improve the stability of the protein. For this 
purpose, several different constructs were tried starting with a single (V172L) and a 
triple (D197Y; I198S; I199F) mutant as illustrated in Figure 9. 
 
 
 
 
 
 
 
 
 
The mutants were then processed as detailed in the Methods section and the 
supernatant and pellet fractions for each one were analyzed by 15% SDS-PAGE, with 
the results being shown in Figure 10. 
 
  
Fig.9 - KtrA C-terminal core constructs representation. Amino acids of interest are highlighted in sticks and cavities are 
shown in surface. a) Valine172 change to Leucine. Valine is shown in yellow (upper panel) and Leucine in red (lower panel). 
b) Aspartate197, Isoleucine198 and Isoleucine199 change to Tyrosine, Serine and Phenilalanine respectively. Aspartate is 
shown in yellow, Isoleucine198 in dark blue and Isoleucine199 in orange (upper panel). Tyrosine is shown in red, Serine in 
green and Phenilalanine in cyano (lower panel). 
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Fig.10 - SDS-PAGE gel of KtrA WT and respective C-terminal mutants. Each protein was lysed by sonication and 
centrifuged. Soluble fractions (Supernatant) and pellet fractions resuspended in lysis buffer were loaded on a 15% SDS 
gel. S refers to the supernatant fraction and P to the pellet fraction. The asterisk (*) marks the band corresponding to 
KtrA in the soluble fractions. 
 
The band analysis of the gel shows that the V172L KtrA mutant is present in 
both the supernatant and pellet fractions, as a band with molecular weight of around 25 
kDa that is similar to KtrA WT. However, the triple mutant D197Y;I198S;I199F is 
present only in the pellet fraction. This indicates that the mutations introduced were not 
tolerated by the protein, probably resulting in an abnormal conformation that caused it 
to become completely insoluble and remain in the pellet fraction. 
Instead of changing three residues at once, an attempt was made to mutate 
only one of the intended residues, I199F. Nonetheless, even just a single-point 
mutation caused the protein to remain in the pellet fraction, as can be seen in Figure 
11. This shows that KtrA is very sensitive to mutations in that area, and the 
D197Y;I198S,I199F and I199F mutants were not pursued further. Mutants that are able 
to remain partially in the supernatant (soluble) fraction like V172L were further 
characterized. 
Within the strategy of increasing the stability of the protein, we were also 
concerned about the potential destabilizing effect of cysteine oxidation. There are 4 
cysteines in KtrA, some of which are partially buried within the protein core. The mutant 
(C22V;C178V;C190S;C204S) was available in the lab and it was known to be soluble 
but it had not been fully characterized in terms of stability. We tried therefore to develop 
a combination mutant using V172L and the cysteineless KtrA. This mutant was named 
KtrA Cysless;V172L and, as shown in Figure 11, it doesn’t render the protein insoluble, 
making it an interesting target for further studies. 
 
1-Protein Marker 
2-KtrA WT –S 
3-KtrA WT- P 
4- D197Y; I198S; I199F-S 
5- D197Y; I198S; I199F-P 
6-V172L-S 
7- V172L-P 
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Fig.11 - SDS-PAGE gel of KtrA C-terminal Mutants. Each protein was lysed by sonication and centrifuged. Soluble 
fractions (Supernatant) and pellet fractions resuspended in lysis buffer were loaded on a 15% SDS gel. S refers to the 
supernatant fraction and P to the pellet fraction. The asterisk (*) marks the band corresponding to KtrA in the soluble 
fractions. 
 
Exposed surface 
 
This approach is based upon previous crystallography studies [49-51] that used 
the SER (surface entropy reduction) technique. This involves mutating residues with 
longer side chains at the surface of proteins and introducing residues with smaller side 
chains, which leads to the formation of crystals with better diffraction. The diffraction 
improvement occurs due to the less conformational liberty given to the side chains of 
residues involved in crystal contacts. By using smaller residues, the entropy necessary 
for crystal contacts is diminished, thereby promoting crystal formation and leading to 
higher resolution structures. 
For this strategy, several residues with long side chains, including lysines, 
arginines and glutamates, exposed at the surface of the KtrA C-terminus                 
(see Figure 12), were mutated to smaller residues. The mutations tried were:              
1) R160H;K161H 2) K165H 3) E196N 4) R200H;E201D;Q202N 5) K212H,                   
6) K212H;R216H and 7) E201A;Q202G. 
  
1-Protein Marker 
2-Cysless;V172L –S 
3-Cysless;V172L P 
4-Protein Marker 
5-I199F-S 
6-I199F-P 
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1-Protein Marker 
2-E196N –S 
3-E196N- P 
4-K165H-S 
5-K165H-P 
6-R160H;K161H-S 
7- R160H;K161H-P 
8- R200H;E201D;Q202N-S 
9- R200H;E201D;Q202N-P 
10- Protein Marker 
11-K212H-S 
12-K212H-P 
13- Protein Marker 
14-K212H;R216H-S 
15-K212H;R216H-P 
16- Protein Marker 
17- E201A;Q202G-S 
18-E201A;Q202G-P 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The constructs were processed as for the cavity filling strategy and analyzed by 
SDS-PAGE as shown in Figure 13. The electrophoresis shows that, of all the mutants 
tried, only three are present in both the supernatant and the pellet fractions: K212H, 
E201A;Q202G and R200H;E201D;Q202N. All remaining mutants are only in the pellet 
fraction, indicating that the mutations are not tolerated, making KtrA insoluble.  
  
 
 
 
 
 
 
 Fig.13 – SDS- PAGE gels of KtrA C-terminal exposed residues constructs. Each protein was lysed by sonication and 
centrifuged. Soluble fractions (Supernatant) and pellet fractions resuspended in lysis buffer were loaded on a 15% SDS gel. 
S refers to the supernatant fraction and P to the pellet fraction. The asterisk (*) marks the band corresponding to KtrA in the 
soluble fractions. 
 
 
Fig.12 - Structural representation of KtrA C-terminal mutations for the exposed surface strategy. On the top panel is 
shown the crystal lattice representation of Figure 8 with the mutated residues highlighted in one of the C-terminals. 
On the lower panel is shown a close up view of the original residues on the left and of the mutated ones on the 
right. Each construct described in the text is represented in a different color: 1) green; 2) yellow; 3) cyan; 4) 
magenta and 5) gray. Constructs 6) and 7) are not shown in the figure. 
FCUP 
Biochemical studies of a membrane protein: The KtrAB ion transporter 
20 
 
1- Protein Marker 
2- CysLHDN-S 
3- CysLHDN-P 
 
The next step consisted in creating a C-terminal mutant combining both 
strategies that would be the best candidate to use in crystallization studies. In order to 
accomplish this, the R200H;E201D;Q202N mutations that worked from the exposed 
surface strategy were incorporated by site directed mutagenesis in the KtrA 
Cysless;V172L mutant from the cavity filling strategy, generating a construct that was 
named KtrA CysLHDN. The new construct was processed as before and checked by 
SDS-PAGE. As depicted in Figure 14, CysLHDN is present in both fractions 
(supernatant and pellet) like KtrA WT. 
 
 
 
Fig.14 - SDS-PAGE gel of KtrA C-terminal mutant CysLHDN. Protein was lysed by sonication and centrifuged. Soluble 
fraction (Supernatant) and pellet fraction resuspended in lysis buffer were loaded on a 15% SDS gel. S refers to the 
supernatant fraction and P to the pellet fraction. The asterisk (*) marks the band corresponding to KtrA in the soluble 
fraction. 
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        Superdex 200 standard elution volumes: 
1. Thyroglobulin (MW 669 kDa) ~10.5mL  
2. Ferritin (MW 440 kDa) ~ 12 mL  
3. Human IgG (MW 150 kDa) ~ 13 mL  
4. Human transferrin (MW 81 kDa) ~ 14 mL  
5. Ovalbumin (MW 43 kDa) ~ 16 mL  
6. Myoglobin (MW 17.6 kDa) ~ 18mL  
7. Vitamin B12 (MW 1.355 kDa) ~ 21 mL  
 
 
Protein Purification 
 
For relevant constructs previously evaluated by SDS-PAGE, it was important to 
discern if they could be purified.   
KtrA C-terminal mutants were purified as wild-type KtrA (see the Methods 
section). The size exclusion chromatograms obtained are shown in Figure 15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.15 - KtrA C-terminal mutants size exclusion chromatography chromatograms. Protein peak elutes in the Superdex 
200 column between 12 and 14 mL. Nucleotide peak elutes at around 20 mL. 
 
As can be observed in the chromatograms, every purified mutant elutes at 
roughly 12.5 mL. Additionally, there is no peak in the void volume of the column (8mL), 
meaning that no aggregation occurs. The second peak around 20 mL corresponds to 
ADP or ATP.  
These results clearly show that the introduced mutations don’t drastically 
change the general behaviour of the protein, since all mutants exhibit a profile identical 
to the native full-length KtrA. In particular, the results indicate that the mutations do not 
affect greatly the assembly of the octameric ring.  Therefore it is reasonable to assume 
that the constructs are good tools to be used in the attempt to improve the resolution of 
the KtrA structure.  
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KtrA C-terminal Mutants Stability 
 
In order to determine if the mutations introduced were indeed improving the 
stabilization of the protein, KtrA WT and the most promising mutants were submitted to 
a thermal shift assay using the fluorescent dye Sypro Orange. When this dye is added 
to a properly folded protein solution, its fluorescence signal is quenched in the aqueous 
environment. With an increase of temperature, the protein unfolds exposing its 
hydrophobic regions and Sypro Orange binds to these regions, leading to an increase 
in the Sypro Orange fluorescence signal. 
The change in fluorescence intensity is plotted as a function of the temperature, 
typically generating a thermal denaturation curve with sigmoid shape (melting curve). 
Protein stability is then evaluated by the melting temperature (Tm), which corresponds 
to the midpoint temperature of the transition between folded and unfolded states of the 
protein and is estimated from the inflexion point of the melting curve, by plotting its 1st 
derivative [52-54]. A protein with higher melting temperature is therefore considered 
more stable. 
In this case, KtrA WT and its mutants were purified and incubated with Sypro 
Orange at 1.5 uM concentration. Thermal stability was measured by performing a 
thermal denaturation curve, using a temperature range from 25 to 70ºC. 
The conditions for preparation of the protein for the thermal stability assay were 
first evaluated. In method A, the native full-length KtrA was eluted from ADP-agarose 
affinity beads using only ADP as a ligand. This ligand was kept throughout the whole 
purification process except during size exclusion chromatography, where ADP was 
removed from the solution. After elution, the protein was supplemented with 1mM of 
either ATP or ADP and used for the assay. In method B the protein was eluted from the 
ADP-agarose beads with either ATP or ADP. After size exclusion chromatography, the 
batches of protein are supplemented with 1mM of the initial ligand. 
While for the protein with ADP there is no difference between the two 
preparation methods, the thermal stability assay reveals a 4ºC difference in the melting 
temperatures for the protein incubated with ATP. 
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Table 2- Melting temperature (Tm) values obtained for KtrA WT purified with ADP and ATP with the methods 
A and B. 
KtrA WT Tm (ºC) 
ADP bound (method A) 54.97 
ADP bound (method B) 54.20 
ATP bound (method A) 48.63 
ATP bound (method B) 44.70 
 
This fact is an indication that some of the ADP used during the preparation of 
the protein still remains bound to the protein after the size exclusion chromatography. 
As a result, even with the addition of an excess of ATP, the bound ligand appears to 
not completely exchange. These results also show that ATP and ADP affect differently 
the thermal stability of KtrA, with ADP stabilizing the protein almost 10ºC. 
Unfortunately, it is not possible to determine the melting temperature of the apo-protein 
since complete removal of ligand results in precipitation. 
In light of these results, experiments with the mutants were done only with the 
protein prepared by method B. Figure 16 depicts the melting curves and respective first 
derivative for each tested protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.16 - Melting and derivative curves of KtrA WT and respective C-terminal mutants. On the left are represented the melting 
profiles obtained for each protein bound to either ADP or ATP. On the right are the respective 1
st
 derivative curves that allow 
the determination of the melting  temperature(Tm). A single example is shown for each protein. RFU stands for relative 
fluorescence units. 
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The melting temperatures (Tm) obtained for each protein bound to ATP or ADP 
are detailed in Table 2. Figure 17 shows the changes in stability by comparison with 
the WT protein. 
 
Table 2 - Melting temperature (Tm) values and respective standard deviations (SD) obtained for wild-type and 
mutant KtrA proteins in the thermal shift assay. ADP or ATP were used at 1mM concentration for each sample and 
values correspond to an average of 15 repeats each. 
KtrA ADP ATP 
 Tm (ºC) SD Tm (ºC) SD 
WT 54.20 0.32 44.70 0.65 
V172L 56.10 0.39 47.20 0.56 
Cysless 57.73 0.26 50.70 0.25 
Cysless;V172L 60.20 0.66 50.57 0.50 
CysLHDN 58.57 0.37 49.43 2.51 
 
 
 
 
 
 
 
 
 
 
 
 
 
The thermal shift assay demonstrates that all the C-terminal mutants of KtrA 
have a higher melting temperature compared to the wild-type protein independently of 
the ligand bound. 
In proteins bound to ADP, the minimum increase in Tm was roughly 2 degrees 
(for the V172L mutant), displaying a fluorescence transition from 54 to 56 ºC when 
compared to the WT KtrA. The highest increase obtained was 6 degrees for the 
Cysless;V172L mutant with a change from 54 to 60 ºC. 
Fig.17 - Bar graph showing the difference in Tm obtained for each tested mutant by comparison with the KtrA 
WT either with ADP (blue) or ATP (red). 
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In proteins bound to ATP we also see a minimum increase in Tm of 2 degrees 
corresponding to the V172L mutant, and a maximum increase of 6 degrees for the 
Cysless;V172L mutant, transitioning from 45 to 51ºC. However, with ATP there is no 
difference between this mutant and the Cysless mutant while with ADP we could detect 
a change of ~2.5ºC. 
These results clearly indicate that the developed mutants of the KtrA C-terminal 
improve the stability of the protein as expected, since the increase in Tm means that a 
higher temperature is needed for the protein to denature. 
Interestingly, the Tm obtained for proteins bound to ADP is always higher than 
the one obtained for proteins bound to ATP. In the native form of KtrA a 9 degree 
difference in Tm is observed and this difference is more or less maintained for the 
mutants, showing that the protein is more stable when bound to ADP. 
  
FCUP 
Biochemical studies of a membrane protein: The KtrAB ion transporter 
26 
 
Complex formation of the KtrA CysLHDN mutant 
 
Of all C-lobe KtrA mutants, CysLHDN is the one thought to be most prone to 
result in better diffracting crystals. This mutant was shown to greatly improve stability 
for both ADP and ATP bound KtrA and it includes mutations of residues exposed on 
the surface of the protein that diminish the entropy of crystal contacts, making the 
protein less prone to disturbances in the crystal lattice. This should in turn lead to the 
formation of a better diffracting crystal capable of generating a structure with higher 
resolution. 
However, the ultimate goal is to increase the resolution of the KtrAB complex 
structure. Therefore it is necessary to ascertain if the introduced mutations impair 
complex formation between the KtrA octameric ring and the KtrB dimer. 
In order to observe complex formation, purified KtrA CysLHDN and KtrB WT 
were mixed at an apparent ratio of 50:105 (w:w) respectively, since this was the ratio 
previously optimized for the KtrAB WT complex. Complex assembly was then 
evaluated by size exclusion chromatography and collected fractions run on SDS-PAGE 
(see Figure 18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.18 - Purification of the KtrB WT-KtrA CysLHDN complex. Size exclusion fractions collected are 
numbered in the chromatogram (left) and were analysed by 15% SDS-PAGE (right). 
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As depicted in the chromatogram and gel, the KtrA mutant CysLHDN 
assembles with KtrB to form the KtrAB complex. The complex elutes the column 
around 12 mL (fraction 3 in the gel) as previously seen for the KtrAB WT. However, the 
optimal ratio of the two proteins in this case seems to differ from the WT complex and 
needs to be optimized further, since in fraction 8 the peak corresponds only to KtrB 
WT, revealing an excess of the membrane protein. 
In light of this result, this KtrA mutant was considered a good tool for 
crystallization studies of the full transporter. 
 
 
Crystallization of KtrA CysLHDN-ATP 
 
The structures of KtrA bound to both ATP and ADP have recently been 
published [33]. They were determined by X-ray diffraction with a resolution of 3.24 Å for 
the ATP complex and 2.93 Å for the ADP complex. In order to try to improve these 
resolutions, a crystallization screen was performed using the CysLHDN KtrA mutant. 
For this purpose, the ATP-bound mutant was prepared, since the resolution of 
the original structure of the native full-length KtrA-ATP complex is lower than for the 
ADP complex. The sitting-drop vapour diffusion crystallization technique was applied in 
order to determine crystallization conditions. 
Two commercially available crystallization screens, Morpheus and JCSG, were 
tested at room temperature in 96-well plates. Crystallization drops were prepared by 
mixing 1 uL of protein and 1 uL of crystallization buffer. The conditions that lead to the 
formation of crystals for each screen are listed in Table 3 and pictures of the crystals 
obtained are depicted in Figure 19. 
 
Table 3 - Crystallization hits obtained for KtrA mutant CysLHDN bound to ATP. 
Crystallization Condition Screen 
a) 0.1M Amino Acids; 0.1M Buffer System 3 pH 8.5; 10% PEG 4000; 20% 
Glycerol 
Morpheus 
 
b) 10% PEG 6000; 0.1M Bicine pH 9.0 JCSG 
c) 40% MPD; 5% PEG 8000; 0.1M Sodium Calcodylate pH 6.5 JCSG 
 
d) 0.1M MES pH 6.5; 1.6M MgSO4 JCSG 
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Unfortunately, the only condition that we were able to reproduce using reagents 
from the laboratory was condition d). 
This condition was optimized by using a range of concentrations of both MES 
and MgSO4 in a 24-well plate. MES concentrations were either 0.100 M or 0.150 M at 
pH 6.5 whereas MgSO4 ranged from 1.3 to 1.8 M. Crystals similar to those observed 
for condition d) were obtained for almost every combination in this screen but well 
formed single crystals were grown in the presence of 0.100 M MES; 1.5 M MgSO4 
(Figure 20). 
 
 
 
 
 
 
 
 
 
 
Fig.20 - KtrA CysLHDN-ATP crystals obtained in 0.100 M MES pH 6.5; 1.5 M MgSO4. 
 
Fig.19 - Pictures of the crystals obtained for KtrA mutant CysLHDN bound to ATP. Letters a) to d) correspond to the 
conditions shown in Table 3. 
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Several crystals from conditions b) and optimized d) were then analysed by X-
ray diffraction. To do so, the crystals were taken-out of the drop and put into cryo 
solutions before being flash-frozen in liquid nitrogen. Cryoprotectant solutions were 
made in order to preserve the crystal at liquid nitrogen temperatures and minimize the 
effects of x-ray exposure during data collection. For crystals derived from condition d), 
the selected cryo solution had the following composition: 0.1M MES pH 6.5; 1.6M 
MgSO4; 0.5 mM ATP; 30% Glycerol. As for the crystals from condition b), the cryo 
solution used was: 0.1M Bicine pH 9.0, 10% PEG 6000; 0.5 mM ATP; 30% Glycerol. 
Data sets obtained, from crystals from condition b), were processed to 2.8 Å 
resolution, which is an improvement compared to the 3.24 Å previously obtained for 
KtrA WT bound to ATP. 
 
Crystallization of KtrB WT-KtrA CysLHDN- ATP 
After successfully obtaining better diffracting crystals for KtrA bound to ATP, the 
next step was to try to obtain a better structure of the full KtrAB transporter. In order to 
do so, KtrB WT and KtrA mutant CysLHDN-ATP were purified as described in the 
Methods section and mixed with a 50:105 (w:w) KtrA to KtrB ratio. The formed complex 
was then purified by size exclusion chromatography and concentrated to 7 mg/mL for 
crystallization. 
The sitting-drop vapour diffusion method was used with the best crystallization 
condition  previously determined for the KtrAB WT complex bound to ATP (0.1M ADA 
pH6.5; 20% PEG 400; 0.2 M AMS). This condition was used as a starting point for 
setting up a screen with the following concentration range of some of the solution 
components (17-22% PEG 400 and 0.150-0.220M AMS). 
From this screen, two conditions resulted in the formation of crystals (see 
Figure 21): 
 1) 0.200M AMS; 19% PEG 400; 0.1M ADA pH6.5 
 2) 0.200M AMS; 22% PEG 400; 0.1M ADA pH6.5 
 
 
 
 
 
 
 
Fig.21 – Pictures of the crystals obtained for the KtrB WT-KtrA CysLHDN-ATP complex.  
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We also tested a different approach to improve the KtrAB crystals. This 
approach is called HILIDE and has been successfully used to crystallize and 
determine the structure of membrane proteins [55, 56]. This procedure is based on 
the importance of phospholipids for stability of membrane proteins and it involves 
the addition of different amounts of a defined phospholipid to the protein prior to the 
crystallization trial. The full procedure is described in the Methods section but 
briefly, the complex KtrB WT-KtrA CysLHDN bound to ATP was purified by size 
exclusion chromatography and concentrated to 9 mg/mL in the presence of the 
detergent Cymal-6. The transporter was then re-lipidated with the phospholipid 
DOPC at 0, 150 and 300 ug. Each one of these conditions was in turn incubated 
with 1.5; 15 or 30 mM of the detergent Cymal-6 for a total of 9 different samples. 
After processing, 1.2 µL of each protein sample was mixed with 1 µL of 
crystallization buffer in a 24-well plate from a screen based on the original WT 
crystallization condition. 
The HILIDE approach resulted in very small crystals (see Figure 22) and it 
will be necessary to repeat the approach with other phospholipids and to test their 
diffraction properties at a synchrotron X-ray source.  
 
 
 
 
 
 
 
 
Fig.22 – Example picture of crystals obtained for the complex KtrB WT- KtrA CysLHDN-ATP in the HILIDE    
strategy. 
Another approach attempted consisted in using an additive screen                
(Hampton Research HR2-428). To the crystallization condition that gave rise to the 
KtrAB crystals used for structure determination (1 µL protein and 1 µL reservoir 
buffer) we added 0.25 µL of an additive (including organic solvents, divalent 
cations, sugars, aminoacids, lipids, among other compounds) before incubation of 
the drop. However no crystals resulted from this strategy. 
Therefore, crystals from the two stated conditions obtained were analysed 
by X-ray diffraction and some data sets were obtained. However, the information 
didn’t result in a structure of the transporter with better resolution than the one 
already published for the KtrAB WT complex.  
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Crystallization of KtrB WT-KtrA CysLHDN-ADP 
 
The sitting-drop vapour diffusion crystallization technique was also applied in an 
attempt to obtain a crystallization condition for the KtrB WT-KtrA CysLHDN complex 
but bound to ADP instead of ATP. An initial trial was performed using an in-house 
crystallization screen. This screen is here referred as SB screen and mixes different 
salts, with six different pH and two different PEGs in each condition. 
This screen revealed three crystal forming conditions shown in Figure 23: 
1) 0.1M KNa; 10% PEG 4000; 0.1M Na Acetate pH 4.6 
2) 1M NaCl; 10% PEG 4000; 0.1M HEPES pH 7.5 
3) 1M NaCl; 10% PEG 4000; 0.1M ADA pH 6.5 
 
 
 
 
 
 
Fig.23 - Crystals obtained with SB screen for the KtrB WT-KtrA CysLHDN-ADP complex. From left to right are 
represented conditions 1, 2 and 3, respectively. 
 
This work is still in progress, since the crystals obtained still need to be 
optimized for X-ray analysis. 
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Cyclic di-AMP stability effect on KtrA 
Recently, Corrigan and colleagues have shown that c-di-AMP does not bind to 
the N-terminal of KtrA from S.aureus [35]. Instead, they showed that this nucleotide 
binds to a truncated form of KtrA containing only the C-terminal region [35]. These 
findings made us wonder if this binding occurs in the KtrA from B.subtilis and, if so, 
what might be the nature of the binding site and how does the nucleotide affect the 
regulation of the transporter. 
In order to answer some of these questions, we started by evaluating the effect 
of cyclic dinucleotides in the thermal stability of native full-length KtrA using the thermal 
shift assay described above. This technique has been used before to determine if small 
molecules, including c-di-GMP, bind to proteins [57-60]. KtrA was purified with either 
ATP or ADP at 1 mM concentration and supplemented with 250 uM of different cyclic 
nucleotides. The nucleotides tested were: c-di-AMP, c-di-GMP, c-di-IMP and cAMP. 
Although this last one is not a cyclic dinucleotide, it is a known relevant biological 
regulator and it would be interesting to see if the protein shows specificity for the 
dinucleotide form or not. 
 The fluorescence transitions observed in the form of melting curves are shown 
in Figure 24 and the melting temperatures obtained from this study are shown in Table 
4. Figure 25 illustrates the difference in Tm obtained for each combination of KtrA with 
either ATP or ADP and cyclic nucleotide in comparison with the non-treated protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig.24 - Melting and corresponding 1
st
 derivative curves for KtrA WT with and without cyclic nucleotides. On the left are the 
melting profiles obtained for treated and non-treated KtrA bound to either ADP or ATP. On the right are the respective 1
st
 
derivative curves that allow the determination of the melting temperature(Tm). A single example is shown for each protein. RFU 
stands for relative fluorescence units. 
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Table 4- Melting temperature (Tm) values and respective standard deviations (SD) obtained in the thermal 
shift assay. ADP or ATP were at a concentration of 1mM in each sample and values correspond to an average of 15 
repeats for non treated (NT) native KtrA and of 6 repeats for KtrA treated with nucleotides. 
KtrA-WT ADP ATP 
 Tm (ºC) SD Tm (ºC) SD 
NT 54.20 0.32 44.70 0.65 
c-di-AMP 56.92 0.20 44.17 0.61 
c-di-GMP 54.00 0.00 43.58 0.58 
c-di-IMP 53.92 0.20 44.00 2.21 
c-AMP 55.00 0.00 46.33 0.86 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
These results clearly show that, when KtrA is bound to ADP, c-di-AMP 
contributes to the stabilization of the protein, leading to a change in Tm from ~54 to 
~ 57 ºC. Moreover, this effect is specific to this cyclic dinucleotide since all other tested 
display roughly the same melting temperature as the non-treated (NT) KtrA. In the case 
of cyclic AMP, a slight increase is observed when compared to the non treated KtrA, 
however this increase is clearly lower since it amounts to less than 1ºC, probably 
meaning that the KtrA binding affinity is lower for cAMP than c-di-AMP. 
Fig.25 - Bar graphs illustrating the difference in melting temperatures (Tm) obtained for KtrA WT treated with 
various cyclic dinucleotides and cAMP, in comparison with non-treated protein. The left graph refers to KtrA 
with ADP and the right graph to KtrA with ATP. 
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In contrast, with KtrA bound to ATP all cyclic dinucleotides caused a decrease 
in the melting temperature. cAMP was the only molecule tested that increased (less 
than 2ºC) the Tm when compared with the non-treated protein. 
In light of these results, we conclude that the only cyclic dinucleotide tested that 
significantly increases the stability is c-di-AMP. However this only occurs when the 
protein is bound to ADP since no effect is observed in the ATP bound protein. 
These results suggest that KtrA binds c-di-AMP and that the conformational 
change in the octameric ring induced by ATP alters the binding site of c-di-AMP 
reducing the ligand’s affinity. 
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Binding of c-di-AMP to KtrA 
 
In order to better understand the binding of c-di-AMP to KtrA, an isothermal 
titration calorimetry (ITC) assay was used. This technique measures the heat change 
associated with the mixing of two components, usually a protein and a ligand. The 
ligand is titrated into the protein solution through several injections and the heat, either 
released or taken-up, is measured by determining the power needed to maintain a 
constant temperature in relation to a reference cell containing water. This heat is 
proportional to the amount of ligand that binds to the protein in each injection. With the 
progress of the titration, the binding sites eventually get saturated and the reaction 
heats tend to zero. The obtained binding isotherm can then be used to retrieve several 
parameters of the interaction: the binding enthalpy, the equilibrium binding affinity, Ka 
(Ka=1/Kd), and the stoichiometry of interaction or number of binding sites (n) [61]. 
 Native full-length KtrA was purified with either ATP or ADP as described in the 
Methods section. The protein concentration was at 30 uM and ATP or ADP were at 
1mM concentration. This protein solution was titrated at 25ºC with c-di-AMP at a 
concentration of 300 uM. 
 
 
 
 
 
 
 
 
 
 
Fig.26 - Interaction of KtrA bound to ADP with c-di-AMP by isothermal titration calorimetry (ITC). A representative assay 
is shown. On the left, the thermogram (thermal power vs. time) is shown after baseline correction. The right panel shows 
the integrated heat release as a function of the molar ratio of c-di-AMP to KtrA-ADP. 
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Regarding KtrA WT bound to ADP, the experiment shows an exothermic profile 
with c-di-AMP binding to the protein (see Figure 26). The integrated heat release was 
normalized according to the heat of dilution of c-di-AMP determined by titrating buffer 
alone with the compound (see Figure 27) and fitting was achieved with a one binding 
site model in Origin. 
 
 
 
 
 
 
 
 
 
Fig.27 - Thermogram depicting the heat of dilution of c-di-AMP titrated into buffer. A representative assay is shown. 
 
The estimated enthalpy for the reaction is of -12 kcal/mol, with a Kd of 12 uM 
and a stoichiometry of interaction (n) of 0.5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
In the assay performed with KtrA bound to ATP, using similar conditions, the 
amount of heat exchanged with the c-di-AMP titration is much smaller than for         
KtrA-ADP (see left panel in Figure 29).  This is consistent with the thermal shift assay 
results were c-di-AMP does not improve the stability of the protein, when KtrA is bound 
to ATP and it strongly indicates that c-di-AMP does not bind to KtrA-ATP. 
Fig.28 - Interaction of KtrA bound to ATP with c-di-AMP by isothermal titration calorimetry (ITC). A representative assay 
is shown. On the left, the thermogram (thermal power vs. time) is shown after baseline correction. The right panel shows 
the heat release as a function of the molar ratio of c-di-AMP to KtrA-ATP. 
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Overall, these results confirm the binding of c-di-AMP to KtrA-ADP but not to 
KtrA-ATP. However, the affinity determined by us is much lower than the one 
previously seen in S.aureus, where the Kd obtained was roughly 64 nM [35].The basis 
for this difference is not clear at the moment but it may just reflect differences in amino 
acid sequence between the two proteins. 
A simple analysis of the KtrA structure led us to propose a putative binding site 
for c-di-AMP that explains some of the properties that we have determined. There is a 
cavity formed by the C-terminal regions of the KtrA dimers in the octameric ring (see 
Figure 29) which appears to have the right volume and shape to accommodate a cyclic 
dinucleotide molecule. 
 
Fig.29 - C-di-AMP putative binding pocket in the C-terminal of KtrA. The KtrAB transporter is represented in a side view, 
with KtrB dimer colored orange and potassium ions in magenta. KtrA octameric ring is shown with the N-terminals 
colored white and the C-terminals colored alternately blue and red to evidence the KtrA dimers. The putative binding 
pocket is highlighted in surface and c-di-AMP is shown in sticks. 
This site is shared between the two C-terminal regions of a KtrA dimer within 
the octameric ring, providing therefore an explanation for the stoichiometry of 0.5 
determined by ITC. In addition the position of the binding site also can explain the 
differences between cyclic di-AMP binding to KtrA-ADP or KtrA-ATP since the 
structural relationship between the two C-terminal regions of a KtrA dimer changes 
when the protein binds one or the other ligand and this is reflected in the structural 
features of this putative binding site. This putative ligand binding site could be explored 
through mutagenesis in the future.  
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Fig.30 - Example of the crystals obtained for KtrA-ADP-c-diAMP. On the left is a picture of crystals formed with 
conditions from the Morpheus screen. On the right is a picture of crystals formed with the handmade screen. 
Crystallization of KtrA WT-ADP with c-di-AMP 
 
The results from both the thermal shift assay and the ITC show binding of c-di-
AMP to KtrA when the protein is bound to ADP and not ATP. Therefore we tried to 
obtain a crystallization condition for this form of the protein in order to discern the exact 
binding site of the cyclic dinucleotide. 
Several crystallization screens were tested using the sitting-drop vapour 
diffusion method (Table 5) and the crystallization conditions found are shown in Table 6 
and Figure 30: 
 
Table 5 - Crystallization screens tested with KtrA-ADP-c-di-AMP. 
Screens tested c-di-AMP 
Concentration (uM) 
ADP 
Concentration 
(mM) 
Protein 
Concentration 
(mg/mL) 
Temperature (ºC) 
Morpheus 300 1 10 20 
Wizard 300 1 10 20 
JCSG 300 1 10 20 
Handmade Screen 300 1 10 20 
 
 
Table 6 - Crystallization hits obtained for KtrA-ADP-c-di-AMP. 
Crystallization Condition Screen 
0.12M Ethylene Glycols; 0.1M Buffer System 1 pH 6.5; 
10% PEG 4000; 20% Glycerol 
Morpheus 
 
0.12M Monosaccharides; 0.1M Buffer System 1 pH 6.5; 
10% PEG 4000; 20% Glycerol 
Morpheus 
 
0.12M Amino Acids; 0.1M Buffer System 1 pH 6.5; 10% 
PEG 4000; 20% Glycerol 
Morpheus 
 
0.2 M KCl; 8% PEG 4000; 0.1M ADA pH 6.5 Handmade 
Screen 
0.2 M KCl; 11% PEG 4000; 0.1M NaCitrate pH 5.6 Handmade 
Screen 
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Hits were further refined using three different strategies carried out in 24-well 
plates, see full description in the Methods section. 
The first strategy was based in the crystallization condition 0.2 M KCl; 11% PEG 
4000; 0.1M NaCitrate pH 5.6. Conditions screened were 0.1M NaCitrate pH 5.6, 7-10% 
PEG 4000, 50-225 mM KCl and either 0, 10 or 20% Glycerol. The second strategy was 
based on the crystallization condition 0.2 M KCl; 8% PEG 4000; 0.1M ADA pH 6.5. 
Screened conditions were similar to the previous screen except that 0.1M ADA pH 6.5 
was used instead of 0.1M NaCitrate pH 5.6. 
The final strategy was based on the conditions that resulted from the Morpheus 
screen, which are all very similar. In this case, screened conditions used included       
6-11% PEG 4000 and 5-20% Glycerol. 
Unfortunately, this refinement did not improve the crystals formed, since they 
were very similar to the initial ones. 
These crystals were then taken out of the drop, immersed in a cryoprotectant 
solution (10% PEG 4000, 0.1M ADA pH 6.5, 0.5 mM ADP, 150 uM c-di-AMP and 30% 
Glycerol) and flash-frozen in liquid nitrogen. 
Crystals were then analysed by X-ray diffraction, but the data sets collected 
have a low resolution that doesn’t allow the detection of c-di-AMP in the structure. 
Therefore it is necessary to improve these crystallization conditions further or find 
better ones in order to be able to determine the KtrA binding site for this nucleotide. 
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Future Perspectives 
 
Future work on the KtrAB project entails the optimization of crystallization 
conditions for both the KtrB WT-KtrA CysLHDN complex and KtrA-ADP-c-di-AMP, in 
order to get a structure of the transporter with better resolution than the existing one in 
the first case, and to discern the binding site of c-di-AMP in KtrA in the second case. 
This can be achieved by testing new crystallization screens and applying different 
crystallization techniques such as hanging drop, at different temperatures. 
Moreover, it is still imperative to understand better the binding of c-di-AMP to 
KtrA. In particular it would be interesting to determine if binding affinity of ATP and ADP 
vary with the presence of c-di-AMP. This would also help to clarify if the binding is 
dependent on the KtrA octameric ring conformation, as suggest by the results shown 
here for KtrA-ADP and KtrA-ATP. 
It would also be interesting to see if c-di-AMP plays a role in the function of the 
transporter KtrAB and that can be discerned, for example, through radioactive flux 
assays. 
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Methods 
KtrA constructs mutagenesis 
KtrA C-terminal mutants were made by site-directed mutagenesis using the 
QuikChange Site-Directed Mutagenesis Kit from Agilent. KtrA from B.subtilis is cloned 
in a pET-24d vector. The reaction was the following: 5 uL 10X Pfu Buffer; 3 uL (30 ng) 
dsDNA template; 1uL (125ng) of oligonucleotide primers forward and reverse; 2.5 uL 
DMSO; 1 uL dNTPmix; ddH2O to a final volume of 50 uL and 1 uL PfuTurbo DNA 
polymerase (2.5 U/uL). The prepared reactions were then subjected to a temperature 
cycling using a T100 Thermal Cycler (Bio-Rad) with the following conditions:   
 
Table 5- PCR conditions used to prepare the KtrA C-terminal mutants. 
Segment Cycles Temperature Time 
1 1 95 ºC 4 minutes 
 
2 
 
17 
95 ºC 1 minute 
55ºC 1 minute 
68ºC 15 minutes 
3 1 68 ºC 10 minutes 
 
Afterwards, each reaction was incubated with 1 uL Dpn I restriction enzyme (10 
U/uL) for 2h at 37 ºC to digest the parental (nonmutated) dsDNA. Each PCR product 
was then transformed in E.coli DH5-ɑ strain and a resulting colony was grown in LB 
with 50 ug/mL Kanamycin at 37 ºC for 16h at 225 rpm. DNA was isolated using a ZR 
Plasmid Miniprep Classic kit (Zymo Research) following the manufacturer’s 
instructions. 
The nucleotide sequence of each mutant was verified by DNA sequencing to 
confirm that the desired mutation was made and no other mutation was incorporated 
during the polymerase chain reaction (PCR). 
The primers used to make each mutant were designed with the QuikChange 
Primer Design online tool from Agilent and are shown in the following table. Bases 
changed are highlighted in red: 
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Table 6- Primers and Templates used to prepare the KtrA C-terminal mutants. 
KtrA Mutant Template Primers 
 
 
V172L 
 
 
KtrA WT 
Forward: 
5'-TTGATTCAAAATCGATTATTGACCTGAATTTAAGAGCAAAGTACGG-3' 
Reverse: 
5'-CCGTACTTTGCTCTTAAATTCAGGTCAATAATCGATTTTGAATCAA-3' 
 
I199F 
 
KtrA WT 
Forward: 
5’- CGCGCCTGAAGACATCTTTCGCGAGCAAGATTG -3’  
Reverse: 
5’- CAATCTTGCTCGCGAAAGATGTCTTCAGGCGCG -3’ 
 
E201A; Q202G 
 
KtrA WT 
Forward: 
5'-CCTGAAGACATCATTCGCGCGGGAGATTGCCTGGTGATCATG-3' 
Reverse: 
5'-CATGATCACCAGGCAATCTCCCGCGCGAATGATGTCTTCAGG-3' 
 
D197Y; I198S; I199F 
 
KtrA WT 
Forward: 
5'-TATCTGTCTTTCCCCCGCGCCTGAATATAGCTTTCGCGAGCAAGATTG-3 
Reverse: 
5'-CAATCTTGCTCGCGAAAGCTATATTCAGGCGCGGGGGAAAGACAGATA-3' 
 
 
V172L;E201A;Q202G 
 
E201A;Q202G 
Forward: 
5'-TTGATTCAAAATCGATTATTGACCTGAATTTAAGAGCAAAGTACGG-3' 
Reverse: 
5'-CCGTACTTTGCTCTTAAATTCAGGTCAATAATCGATTTTGAATCAA-3' 
 
 
       Cysless;V172L 
 
Cysless 
Forward: 
5'-TTGATTCAAAATCGATTATTGACCTGAATTTAAGAGCAAAGTACGG-3' 
Reverse: 
5'-CCGTACTTTGCTCTTAAATTCAGGTCAATAATCGATTTTGAATCAA-3' 
 
K212H 
 
KtrA WT 
Forward: 
5’- CCTGGTGATCATGGGCCACAAACATGATATTAAACGTTTTGAAAACGA -3’ 
Reverse: 
5’- TCGTTTTCAAAACGTTTAATATCATGTTTGTGGCCCATGATCACCAGG -3’ 
 
 
K165H 
 
 
KtrA WT 
Forward: 
5’- TGGCTACGCGCAAGCTTGATTCACATTCGATTATTGACCTG -3’ 
Reverse: 
5’- CAGGTCAATAATCGAATGTGAATCAAGCTTGCGCGTAGCCA -3’ 
 
E196N 
 
KtrA WT 
Forward: 
5’- CTTTCCCCCGCGCCTAATGACATCATTCGCGAG -3’ 
Reverse: 
5’- CTCGCGAATGATGTCATTAGGCGCGGGGGAAAG -3’ 
 
K212H;R216H 
 
K212H 
Forward: 
5’- GGGCCACAAACATGATATTAAACATTTTGAAAACGAAGGGATGTAG -3’ 
Reverse: 
5’- CTACATCCCTTCGTTTTCAAAATGTTTAATATCATGTTTGTGGCCC -3’ 
 
 
R160H;K161H 
 
 
KtrA WT  
Forward: 
5’- TTGTCGAGCTGCTGGCTACGCACCATCTTGATTCAAAATCGATTATTG -3 
Reverse: 
5’- CAATAATCGATTTTGAATCAAGATGGTGCGTAGCCAGCAGCTCGACAA -3’ 
 
R200H,E201D;Q202N 
 
KtrA WT 
Forward: 
5’- CGCGCCTGAAGACATCATTCACGATAATGATTGCCTGGTGATCATGGG -3’ 
Reverse: 
5’- CCCATGATCACCAGGCAATCATTATCGTGAATGATGTCTTCAGGCGCG -3’ 
 
CysLHDN 
       
Cysless;V172L 
Forward: 
5’- CGCGCCTGAAGACATCATTCACGATAATGATAGCCTGGTGATCATGGG -3’ 
Reverse: 
5’- CCCATGATCACCAGGCTATCATTATCGTGAATGATGTCTTCAGGCGCG -3’ 
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Protein expression and purification 
 
Tag-less KtrA and respective mutants were over-expressed in E. coli BL21 
(DE3) strain after growth to an OD600 (optical density at 600 nm) of 0.6 at 37 °C in LB 
media and approximately 16 h induction by 0.5 mM IPTG and 2% ethanol at 20 °C. Cell 
lysis was done in Buffer A (50 mM Tris-HCl pH 7.5, 50 mM KCl, 5mM DTT) 
supplemented with protease inhibitors (1ug/mL Leupeptine and Pepstatine A and 1mM 
PMSF) using a prechilled cell cracker Emulsiflex-C5 (Avestin). For solubility tests, 
lysate was analyzed immediately in SDS-PAGE. Otherwise, spin-cleared lysate was 
loaded into an anion exchange column Hi-Trap Sepharose Q HP (5mL) attached to an 
ÄKTA purifier UP-10. KtrA was eluted using a KCl gradient (50mM to 1 M). Eluted 
fractions containing KtrA were pooled and incubated with an ADP-agarose resin 
(Innova Biosciences) overnight at 4 °C with gentle agitation. Beads were then washed 
thoroughly with Buffer B (50 mM Tris-HCl pH 8.0, 150 mM KCl, 1mM TCEP) and 
protein was eluted in buffer B supplemented with either 5 mM ADP or ATP. Protein was 
then concentrated to ~5 mg/ml in a Sartorius Vivaspin column (15mL with Mw-cutoff of 
30 kDa) and further purified by size exclusion chromatography with a Superdex-S200 
(GE Healthcare) column using buffer C (50 mM Tris-HCl pH 7.5, 150 mM KCl, 5 mM 
DTT). Eluted KtrA was supplemented with 1 mM ATP or ADP from a 100 mM stock in 1 
M Tris-HCl pH 7.5. Protein concentration was determined with a colorimetric assay 
(Bio-rad) and measuring A595nm or by the Direct Detect Spectrometer (EMD Millipore). 
‘N-His6-KtrB cloned in a modified pET-24d vector (Novagen) was over-
expressed in E. coli BL21 (DE3) strain. Cells were grown in LB media at 37 °C to an 
OD600 of 1.1 and induced by 0.5 mM IPTG and 1mM BaCl2 for 2.5 h. Cells were then 
lysed as described for KtrA in buffer D (50 mM Tris-HCl pH 8.0, 120 mM NaCl, 30 mM 
KCl) supplemented with protease inhibitors. KtrB was extracted from the cell lysate with 
40 mM DDM (n-dodecyl-β-D-maltoside, solgrade from Anatrace) overnight at 4 °C with 
gentle agitation. Spin-cleared lysate was loaded into a Talon metal affinity resin 
(Clontech) and washed with Buffer E (50 mM Tris-HCl pH 8.0, 120 mM NaCl, 30 mM 
KCl, 1 mM DDM). The column was then washed with buffer D supplemented with 20 
mM imidazole. KtrB was eluted with buffer D supplemented with 150 mM imidazole and 
immediately diluted in buffer D supplemented with 15 mM DTT and 1.5 mM TCEP 
(both wash and elution were monitored with a UV-detector-attached chart-recorder). 
Eluted fractions were concentrated to ~2.5 mg/ml and incubated overnight at 4 °C with 
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thrombin for his-tag cleavage. At this point the protein was directly used for KtrAB 
complex assembly. 
KtrAB complex was assembled by mixing individually purified KtrA and KtrB 
batches at a pre-defined ratio. The complex was concentrated and further purified by 
size exclusion chromatography in a Superdex-S200 column (GE Healthcare) in Buffer 
F ( 20 mM Tris-HCl pH 8.0; 120 mM NaCl; 30 mM KCl; 5 mM DTT; 1 mM DDM). For 
crystallization, 1mM DDM in Buffer F was replaced by 1.5 mM 6-cyclohexyl-1-hexyl-β-
D-maltoside (cymal-6, anagrade from Anatrace). 
 
Solubility Assay 
 
For solubility assays, cells were lysed in Buffer G (50 mM Tris-HCl pH 7.5, 50 
mM KCl, 0.5 mg/mL Lysozyme) supplemented with protease inhibitors, using a 
Branson sonifier. Sonication conditions used were: output power of 5, 50% duty cycle. 
Cells were sonicated for a total of 6 mins (15 seconds ON/OFF) for each sample. 1mL 
of sonicated sample was then incubated with 0.2 mg/mL DNase in gentle rotation for 
30 minutes, at room temperature, and then centrifuged for 10 minutes at 11500 rpm. 
Supernatants and pellets (ressuspended in 1mL Buffer G) were run on a 15% SDS-
PAGE gel. 
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Thermal Shift Assay 
 
KtrA WT and respective mutants were purified as described in the Protein 
expression and purification section. Samples were prepared in 40 µL reactions 
containing 1.5 uM final concentration of protein, with 1mM of either ATP or ADP, and    
6-fold dilution final concentration of SYPRO Orange Protein Gel Stain (Sigma-Aldrich) 
in Buffer C. In the assays performed with c-di-NMPs (Biolog) or cAMP (Sigma-Aldrich), 
the compounds were used at 250 uM final concentration. The reactions were 
assembled in a 96-well PCR white plate (Bio-Rad) which was then sealed and covered 
in foil paper. The plate was centrifuged for 1min at 1500 rpm to ensure good mixing 
and the assay was performed using the iQ5 real-time PCR detection system (Bio-Rad) 
with the Cy3 optical filter for Sypro Orange detection (Ex: 490/Em: 575 nm). 
Temperature was varied in the 25 to 70 ºC range, with an increment of 0.5 ºC and a 
dwell time at each step of 30 seconds. Recorded data was analysed with the CFX 
Manager (Bio-Rad) and GraphPad Prism 5 softwares. 
 
Isothermal Titration Calorimetry (ITC)  
 
For ITC experiments, KtrA WT was purified as described in the Protein 
expression and purification section and then dialyzed overnight against Buffer H (50 
mM HEPES pH 7.5; 150 mM KCl; 1mM TCEP; 1mM ATP or ADP). 
Titrations were performed using a VP-ITC calorimeter (MicroCal, LLC, 
Northampton, MA, USA) at 25ºC. In the sample cell KtrA WT was present at 30 uM  
with 1mM of ADP or ATP. Cyclic di-AMP (c-di-AMP) was loaded into the injection 
syringe at 300 µM. All samples were centrifuged to remove possible precipitates and 
thoroughly degassed. 
In all titration runs, the first injection had a volume of 2 µL and was followed by 
injections of 10 µL volume. Consecutive injections were separated by 250 seconds to 
allow the peak to return to baseline levels. Heats of dilution were measured in a 
titration of c-di-AMP into buffer alone and subtracted from the titration heats to yield the 
heats of interaction. Data was analyzed with a single binding site model using Origin 
7.0 (Origin Lab Corp., Northampton, MA, USA) software. 
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Crystallization 
 
 Crystallization screens were carried out at room temperature using the     
sitting-drop vapour diffusion method. Experiments were performed in 24 (Cryschem, 
Hampton Research) or 96-well (MRC 2, Swissci, Hampton Research) plates, sealed 
with high performance crystal clear tape (Duck) and stored at 22 ºC. Sitting drops were 
assembled by mixing protein solution and reservoir buffer in a 1:1 ratio for a final 2 µL 
volume drop. For 96-well plates, 75 µL of crystallization solution was placed in the 
reservoir and for 24-well plates, 500 µL were used. 
  
KtrA CysLHDN-ATP 
 
Protein was prepared as described in the Protein expression and purification 
section and concentrated to 10 mg/mL. Initial screening was performed in 96-well 
plates using commercial crystallization screens: Morpheus (Molecular Dimensions) and 
JCSG (Molecular Dimensions) with a total of 96 different buffer conditions each. 
 The crystal forming condition with the better looking crystals (0.1M MES pH 
6.5; 1.6M MgSO4) was then refined by using a 24-well plate with the reservoir 
composition shown below, in order to obtain a good amount of crystals for X-ray 
analysis:  
 
Table 7 - Reservoir composition of the 24-well plate used to refine the best crystals of KtrA CysLHDN-ATP. 
MES pH6.5/MgSO4 MgSO4 1.3 - 1.8 (M) 
 
MES pH 6.5 
0.100 - 0.150 (M) 
0.100/ 1.3 0.100/ 1.4 0.100/ 1.5 0.100/ 1.6 0.100/ 1.7 0.100/ 1.8 
0.150/ 1.3 0.150/ 1.4 0.150/ 1.5 0.150/ 1.6 0.150/ 1.7 0.150/ 1.8 
0.100/ 1.3 0.100/ 1.4 0.100/ 1.5 0.100/ 1.6 0.100/ 1.7 0.100/ 1.8 
0.150/ 1.3 0.150/ 1.4 0.150/ 1.5 0.150/ 1.6 0.150/ 1.7 0.150/ 1.8 
 
Crystals were collected from the drop and immersed in a cryoprotectant solution 
with the following composition: 0.1M MES pH 6.5; 1.6M MgSO4; 0.5 mM ATP; 30% 
Glycerol. The crystals were then flash-frozen in liquid nitrogen and analysed by X-ray 
diffraction. 
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KtrB WT+ KtrA CysLHDN-ATP complex 
 
Initial Screen 
 
KtrB WT and KtrA mutant CysLHDN-ATP were purified as described in the 
Protein expression and purification section and mixed at a 50:105 (w:w) KtrA to KtrB 
ratio. The complex was then purified by size exclusion chromatography and 
concentrated to 7 mg/mL. Initial screening was based in the best crystallization 
condition already obtained for the KtrAB WT complex bound to ATP: 0.1M ADA pH6.5; 
20% PEG 400; 0.2M AMS and performed in two 24-well plates (tables 8 and 9) with the 
following reservoir composition (all wells contain 0.1M ADA pH 6.5): 
 
Table 8- Reservoir composition of the first 24-well plate used to obtain crystallization conditions of the                        
KtrB WT+KtrA CysLHDN-ATP complex. 
AMS/PEG 400 PEG 400 17 – 22 % (v/v) 
 
AMS 
0.150 - 0.220 (M) 
0.150/ 17 0.150/ 18 0.150/ 19 0.150/ 20 0.150/ 21 0.150/ 22 
0.180/ 17 0.180/ 18 0.180/ 19 0.180/ 20 0.180/ 21 0.180/ 22 
0.200/ 17 0.200/ 18 0.200/ 19 0.200/ 20 0.200/ 21 0.200/ 22 
0.220/ 17 0.220/ 18 0.220/ 19 0.220/ 20 0.220/ 21 0.220/ 22 
 
Table 9 - Reservoir composition of the second 24-well plate used to obtain crystallization conditions of the                        
KtrB WT+KtrA CysLHDN-ATP complex. 
AMS/PEG 400 PEG 400 17 – 22 % (v/v) 
 
AMS 
0.180 – 0.210 (M) 
0.180/ 17 0.180/ 18 0.180/ 19 0.180/ 20 0.180/ 21 0.180/ 22 
0.190/ 17 0.190/ 18 0.190/ 19 0.190/ 20 0.190/ 21 0.190/ 22 
0.200/ 17 0.200/ 18 0.200/ 19 0.200/ 20 0.200/ 21 0.200/ 22 
0.210/ 17 0.210/ 18 0.210/ 19 0.210/ 20 0.210/ 21 0.210/ 22 
 
Crystals were collected from the drop and immersed in a cryoprotectant solution 
with the following composition: 0.1M ADA pH 6.5; 45% PEG 400; 0.2M AMS; 1.5 mM 
cymal-6 and 0.5 mM ATP. The crystals were then flash-frozen in liquid nitrogen and 
analysed by X-ray diffraction. 
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HILIDE Screen 
 
KtrB WT and KtrA mutant CysLHDN-ATP were purified as described in the 
Protein expression and purification section and mixed at a 50:105 (w:w) KtrA to KtrB 
ratio. The complex was then purified by size exclusion chromatography and 
concentrated to 9 mg/mL.  
Nine samples with different lipid/detergent concentration ratios were prepared 
for the screen according to table 10: 
 
Table 10 –Lipid/detergent ratios used for the HILIDE Screen. 
 
 
 Re-lipidation: 
 
57 µL of concentrated protein was added to nine glass tubes pre-treated with a 
thin film of the phospholipid 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) from 
Avanti. The film was prepared by placing DOPC, dissolved at 1 mg/mL in chloroform, 
corresponding to 0, 150 and 300 µg, into three glass tubes for each lipid concentration. 
The chloroform was then evaporated using an argon gas stream at room temperature. 
Lipidated protein samples were supplemented with 1.5, 15 or 30 mM of the 
detergent 6-cyclohexyl-1-hexyl-β-D-maltoside (cymal-6, anagrade from Anatrace) from 
a 100mM stock. 
The nine resulting sample tubes were then covered with parafilm and incubated 
for 16 h at 4ºC with agitation at 300 rpm. Afterwards, samples were centrifuged for 15 
minutes at 25 psi in an airfuge; resulting supernatants were used for crystallization.  
Each different sample was incubated in a 24-well plate with the reservoir 
composition shown in Table 8. In this case, 1.2 µL of protein solution was mixed with 1 
µL of reservoir buffer to assemble the drop. 
 
 
 
Cymal-6/ DOPC 0 ug 150 ug 300 ug 
1.5 mM   0 uL (Cymal-6) 
 0 uL (DOPC) 
0 uL (Cymal-6) 
150 uL(DOPC) 
 0 uL (Cymal-6) 
 300uL (DOPC) 
15 mM  6.75 uL(Cymal-6) 
 0 uL (DOPC) 
6.75 uL (Cymal-6) 
 150 uL(DOPC) 
 6.75 uL (Cymal-6) 
 300 uL(DOPC) 
30 mM 14.25 uL(Cymal-6) 
 0 uL (DOPC) 
14.25 uL(Cymal-6) 
 150 uL(DOPC) 
14.25 uL (Cymal-6) 
 300 uL(DOPC) 
FCUP 
Biochemical studies of a membrane protein: The KtrAB ion transporter 
49 
 
Additive Screen 
 
KtrB WT and KtrA mutant CysLHDN-ATP were purified as described in the 
Protein expression and purification section and mixed at a 50:105 (w:w) KtrA to KtrB 
ratio. The formed complex was then purified by size exclusion chromatography and 
concentrated to 7 mg/mL. 
The screen was carried out using 24-well plates with the reservoir composition 
shown in Table 8. The drop (1 µL protein solution + 1µL reservoir buffer) was 
supplemented with 0.25 µL of additive solution, from the additive screen Hampton 
Research HR2-428 for a total of 96 different additive conditions. 
 
KtrB WT+ KtrA CysLHDN-ADP complex 
 
KtrB WT and KtrA mutant CysLHDN-ADP were purified as described in the 
Protein expression and purification section and mixed at a 50:105 (w:w) KtrA to KtrB 
ratio. The complex was then purified by size exclusion chromatography and 
concentrated to 7 mg/mL. 
The crystallization screening was performed in 24-well plates using a 
handmade screen previously developed in the laboratory, named SB screen. This 
screen contains 480 different conditions. The screen composition is listed in the 
Appendix. 
 
KtrA WT-ADP-c-di-AMP 
 
Protein was prepared as described in the Protein expression and purification 
section, concentrated to 10 mg/mL and supplemented with c-di-AMP at 300 uM. Initial 
screening was performed in 96-well plates using commercial crystallization screens: 
Morpheus (Molecular Dimensions), JCSG (Molecular Dimensions) and Wizard 
(Emerald BioSystems) with a total of 96 different buffer conditions each. Additionally, a 
handmade screen developed by us in the laboratory with 672 conditions was also 
tested. The screen composition is detailed in the Appendix.  
Conditions with crystals were refined by using 24-well plates with the reservoir 
composition shown in the tables below: 
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Table 11 - Reservoir composition of the first 24-well plate used to refine the crystallization conditions of KtrA WT-ADP 
with c-di-AMP. Three plates were made with wells containing 0.1M Sodium citrate pH 5.6 and either 0, 10 or 20% 
Glycerol. 
 
 
Table 12 - Reservoir composition of the second 24-well plate used to refine the crystallization conditions of KtrA WT-
ADP with c-di-AMP. Three plates were made with wells containing 0.1M ADA pH 6.5 and either 0, 10 or 20% Glycerol. 
PEG 4000 / KCl KCl 50 – 225 (mM) 
 
PEG 4000 
7 – 10 % (w/v) 
7%/ 50 7%/ 100 7%/ 150 7%/ 175 7%/ 200 7%/ 225 
8%/ 50 8%/ 100 8%/ 150 8%/ 175 8%/ 200 8%/ 225 
9%/ 50 9%/ 100 9%/ 150 9%/ 175 9%/ 200 9%/ 225 
10%/ 50 10%/ 100 10%/ 150 10%/ 175 10%/ 200 10%/ 225 
 
Table 13 - Reservoir composition of the third  24-well plate used to refine the crystallization conditions of  KtrA WT-ADP 
with c-di-AMP. Three plates were made with wells containing 0.1M ADA pH 6.5. 
Glycerol / PEG 4000 PEG 4000 6 – 11 % (w/v) 
 
Glycerol 
5 - 20 % (v/v) 
5%/ 6% 5%/ 7% 5%/ 8% 5%/ 9% 5%/ 10% 5%/ 11% 
10%/ 6% 10%/ 7% 10%/ 8% 10%/ 9% 10%/ 10% 10%/ 11% 
15%/ 6% 15%/ 7% 15%/ 8% 15%/ 9% 15%/ 10% 15%/ 11% 
20%/ 6% 20%/ 7% 20%/ 8% 20%/ 9% 20%/ 10% 20%/ 11% 
 
 
Crystals were collected from the drop and immersed in a cryoprotectant solution 
with the following composition: 10% PEG 4000, 0.1M ADA pH 6.5, 0.5 mM ADP, 150 
uM c-di-AMP and 30% Glycerol. 
The crystals were then flash-frozen in liquid nitrogen and analysed by X-ray 
diffraction. 
  
PEG 4000 / KCl KCl 50 – 225 (mM) 
 
PEG 4000 
7 – 10 % (w/v) 
7%/ 50 7%/ 100 7%/ 150 7%/ 175 7%/ 200 7%/ 225 
8%/ 50 8%/ 100 8%/ 150 8%/ 175 8%/ 200 8%/ 225 
9%/ 50 9%/ 100 9%/ 150 9%/ 175 9%/ 200 9%/ 225 
10%/ 50 10%/ 100 10%/ 150 10%/ 175 10%/ 200 10%/ 225 
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Appendix 
 
Table 14 – Handmade Crystallization Screen Composition. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Conditions: 1- 48         Precipitant: PEG 2000      Salt: Lithium sulphate 0.2M 
PEG / pH pH 5.6 – 8.5 
 
 
 
PEG 2000 
6 – 17 % 
(w/v) 
6%/ 5.6 6%/ 6.5 6%/ 7.5 6%/ 8.5 
7%/ 5.6 7%/ 6.5 7%/ 7.5 7%/ 8.5 
8%/ 5.6 8%/ 6.5 8%/ 7.5 8%/ 8.5 
9%/ 5.6 9%/ 6.5 9%/ 7.5 9%/ 8.5 
10%/ 5.6 10%/ 6.5 10%/ 7.5 10%/ 8.5 
11%/ 5.6 11%/ 6.5 11%/ 7.5 11%/ 8.5 
12%/ 5.6 12%/ 6.5 12%/ 7.5 12%/ 8.5 
13%/ 5.6 13%/ 6.5 13%/ 7.5 13%/ 8.5 
14%/ 5.6 14%/ 6.5 14%/ 7.5 14%/ 8.5 
15%/ 5.6 15%/ 6.5 15%/ 7.5 15%/ 8.5 
16%/ 5.6 16%/ 6.5 16%/ 7.5 16%/ 8.5 
17%/ 5.6 17%/ 6.5 17%/ 7.5 17%/ 8.5 
Conditions: 49- 96       Precipitant: PEG 4000      Salt: Lithium sulphate 0.2M 
PEG / pH pH 5.6 – 8.5 
 
 
 
 
PEG 4000 
6 – 17 % 
(w/v) 
6%/ 5.6 6%/ 6.5 6%/ 7.5 6%/ 8.5 
7%/ 5.6 7%/ 6.5 7%/ 7.5 7%/ 8.5 
8%/ 5.6 8%/ 6.5 8%/ 7.5 8%/ 8.5 
9%/ 5.6 9%/ 6.5 9%/ 7.5 9%/ 8.5 
10%/ 5.6 10%/ 6.5 10%/ 7.5 10%/ 8.5 
11%/ 5.6 11%/ 6.5 11%/ 7.5 11%/ 8.5 
12%/ 5.6 12%/ 6.5 12%/ 7.5 12%/ 8.5 
13%/ 5.6 13%/ 6.5 13%/ 7.5 13%/ 8.5 
14%/ 5.6 14%/ 6.5 14%/ 7.5 14%/ 8.5 
15%/ 5.6 15%/ 6.5 15%/ 7.5 15%/ 8.5 
16%/ 5.6 16%/ 6.5 16%/ 7.5 16%/ 8.5 
17%/ 5.6 17%/ 6.5 17%/ 7.5 17%/ 8.5 
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Conditions: 97- 144     Precipitant: PEG 2000      Salt: Ammonium sulphate 0.2M 
PEG / pH pH 5.6 – 8.5 
 
 
 
 
PEG 2000 
6 – 17 % 
(w/v) 
6%/ 5.6 6%/ 6.5 6%/ 7.5 6%/ 8.5 
7%/ 5.6 7%/ 6.5 7%/ 7.5 7%/ 8.5 
8%/ 5.6 8%/ 6.5 8%/ 7.5 8%/ 8.5 
9%/ 5.6 9%/ 6.5 9%/ 7.5 9%/ 8.5 
10%/ 5.6 10%/ 6.5 10%/ 7.5 10%/ 8.5 
11%/ 5.6 11%/ 6.5 11%/ 7.5 11%/ 8.5 
12%/ 5.6 12%/ 6.5 12%/ 7.5 12%/ 8.5 
13%/ 5.6 13%/ 6.5 13%/ 7.5 13%/ 8.5 
14%/ 5.6 14%/ 6.5 14%/ 7.5 14%/ 8.5 
15%/ 5.6 15%/ 6.5 15%/ 7.5 15%/ 8.5 
16%/ 5.6 16%/ 6.5 16%/ 7.5 16%/ 8.5 
17%/ 5.6 17%/ 6.5 17%/ 7.5 17%/ 8.5 
Conditions: 145- 192     Precipitant: PEG 4000      Salt: Ammonium sulphate 0.2M 
PEG / pH pH 5.6 – 8.5 
 
 
 
 
PEG 4000 
6 – 17 % 
(w/v) 
6%/ 5.6 6%/ 6.5 6%/ 7.5 6%/ 8.5 
7%/ 5.6 7%/ 6.5 7%/ 7.5 7%/ 8.5 
8%/ 5.6 8%/ 6.5 8%/ 7.5 8%/ 8.5 
9%/ 5.6 9%/ 6.5 9%/ 7.5 9%/ 8.5 
10%/ 5.6 10%/ 6.5 10%/ 7.5 10%/ 8.5 
11%/ 5.6 11%/ 6.5 11%/ 7.5 11%/ 8.5 
12%/ 5.6 12%/ 6.5 12%/ 7.5 12%/ 8.5 
13%/ 5.6 13%/ 6.5 13%/ 7.5 13%/ 8.5 
14%/ 5.6 14%/ 6.5 14%/ 7.5 14%/ 8.5 
15%/ 5.6 15%/ 6.5 15%/ 7.5 15%/ 8.5 
16%/ 5.6 16%/ 6.5 16%/ 7.5 16%/ 8.5 
17%/ 5.6 17%/ 6.5 17%/ 7.5 17%/ 8.5 
Conditions192-240      Precipitant: PEG 2000      Salt: Ammonium formate 0.2M 
PEG / pH pH 5.6 – 8.5 
 
 
 
 
PEG 2000 
6 – 17 % 
(w/v) 
6%/ 5.6 6%/ 6.5 6%/ 7.5 6%/ 8.5 
7%/ 5.6 7%/ 6.5 7%/ 7.5 7%/ 8.5 
8%/ 5.6 8%/ 6.5 8%/ 7.5 8%/ 8.5 
9%/ 5.6 9%/ 6.5 9%/ 7.5 9%/ 8.5 
10%/ 5.6 10%/ 6.5 10%/ 7.5 10%/ 8.5 
11%/ 5.6 11%/ 6.5 11%/ 7.5 11%/ 8.5 
12%/ 5.6 12%/ 6.5 12%/ 7.5 12%/ 8.5 
13%/ 5.6 13%/ 6.5 13%/ 7.5 13%/ 8.5 
14%/ 5.6 14%/ 6.5 14%/ 7.5 14%/ 8.5 
15%/ 5.6 15%/ 6.5 15%/ 7.5 15%/ 8.5 
16%/ 5.6 16%/ 6.5 16%/ 7.5 16%/ 8.5 
17%/ 5.6 17%/ 6.5 17%/ 7.5 17%/ 8.5 
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Conditions: 241- 288     Precipitant: PEG 4000      Salt: Ammonium formate 0.2M 
PEG / pH pH 5.6 – 8.5 
 
 
 
 
PEG 4000 
6 – 17 % 
(w/v) 
6%/ 5.6 6%/ 6.5 6%/ 7.5 6%/ 8.5 
7%/ 5.6 7%/ 6.5 7%/ 7.5 7%/ 8.5 
8%/ 5.6 8%/ 6.5 8%/ 7.5 8%/ 8.5 
9%/ 5.6 9%/ 6.5 9%/ 7.5 9%/ 8.5 
10%/ 5.6 10%/ 6.5 10%/ 7.5 10%/ 8.5 
11%/ 5.6 11%/ 6.5 11%/ 7.5 11%/ 8.5 
12%/ 5.6 12%/ 6.5 12%/ 7.5 12%/ 8.5 
13%/ 5.6 13%/ 6.5 13%/ 7.5 13%/ 8.5 
14%/ 5.6 14%/ 6.5 14%/ 7.5 14%/ 8.5 
15%/ 5.6 15%/ 6.5 15%/ 7.5 15%/ 8.5 
16%/ 5.6 16%/ 6.5 16%/ 7.5 16%/ 8.5 
17%/ 5.6 17%/ 6.5 17%/ 7.5 17%/ 8.5 
Conditions: 289- 336  Precipitant: PEG 2000 Salt: Potassium-sodium tartrate 0.2M 
PEG / pH pH 5.6 – 8.5 
 
 
 
 
PEG 2000 
6 – 17 % 
(w/v) 
6%/ 5.6 6%/ 6.5 6%/ 7.5 6%/ 8.5 
7%/ 5.6 7%/ 6.5 7%/ 7.5 7%/ 8.5 
8%/ 5.6 8%/ 6.5 8%/ 7.5 8%/ 8.5 
9%/ 5.6 9%/ 6.5 9%/ 7.5 9%/ 8.5 
10%/ 5.6 10%/ 6.5 10%/ 7.5 10%/ 8.5 
11%/ 5.6 11%/ 6.5 11%/ 7.5 11%/ 8.5 
12%/ 5.6 12%/ 6.5 12%/ 7.5 12%/ 8.5 
13%/ 5.6 13%/ 6.5 13%/ 7.5 13%/ 8.5 
14%/ 5.6 14%/ 6.5 14%/ 7.5 14%/ 8.5 
15%/ 5.6 15%/ 6.5 15%/ 7.5 15%/ 8.5 
16%/ 5.6 16%/ 6.5 16%/ 7.5 16%/ 8.5 
17%/ 5.6 17%/ 6.5 17%/ 7.5 17%/ 8.5 
Conditions: 337- 384  Precipitant: PEG 4000 Salt: Potassium-sodium tartrate 0.2M 
PEG / pH pH 5.6 – 8.5 
 
 
 
 
PEG 4000 
6 – 17 % 
(w/v) 
6%/ 5.6 6%/ 6.5 6%/ 7.5 6%/ 8.5 
7%/ 5.6 7%/ 6.5 7%/ 7.5 7%/ 8.5 
8%/ 5.6 8%/ 6.5 8%/ 7.5 8%/ 8.5 
9%/ 5.6 9%/ 6.5 9%/ 7.5 9%/ 8.5 
10%/ 5.6 10%/ 6.5 10%/ 7.5 10%/ 8.5 
11%/ 5.6 11%/ 6.5 11%/ 7.5 11%/ 8.5 
12%/ 5.6 12%/ 6.5 12%/ 7.5 12%/ 8.5 
13%/ 5.6 13%/ 6.5 13%/ 7.5 13%/ 8.5 
14%/ 5.6 14%/ 6.5 14%/ 7.5 14%/ 8.5 
15%/ 5.6 15%/ 6.5 15%/ 7.5 15%/ 8.5 
16%/ 5.6 16%/ 6.5 16%/ 7.5 16%/ 8.5 
17%/ 5.6 17%/ 6.5 17%/ 7.5 17%/ 8.5 
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Conditions: 385- 432     Precipitant: PEG 2000      Salt: Calcium chloride 0.2M 
PEG / pH pH 5.6 – 8.5 
 
 
 
 
PEG 2000 
6 – 17 % 
(w/v) 
6%/ 5.6 6%/ 6.5 6%/ 7.5 6%/ 8.5 
7%/ 5.6 7%/ 6.5 7%/ 7.5 7%/ 8.5 
8%/ 5.6 8%/ 6.5 8%/ 7.5 8%/ 8.5 
9%/ 5.6 9%/ 6.5 9%/ 7.5 9%/ 8.5 
10%/ 5.6 10%/ 6.5 10%/ 7.5 10%/ 8.5 
11%/ 5.6 11%/ 6.5 11%/ 7.5 11%/ 8.5 
12%/ 5.6 12%/ 6.5 12%/ 7.5 12%/ 8.5 
13%/ 5.6 13%/ 6.5 13%/ 7.5 13%/ 8.5 
14%/ 5.6 14%/ 6.5 14%/ 7.5 14%/ 8.5 
15%/ 5.6 15%/ 6.5 15%/ 7.5 15%/ 8.5 
16%/ 5.6 16%/ 6.5 16%/ 7.5 16%/ 8.5 
17%/ 5.6 17%/ 6.5 17%/ 7.5 17%/ 8.5 
Conditions: 433- 480     Precipitant: PEG 4000      Salt: Calcium chloride 0.2M 
PEG / pH pH 5.6 – 8.5 
 
 
 
 
PEG 4000 
6 – 17 % 
(w/v) 
6%/ 5.6 6%/ 6.5 6%/ 7.5 6%/ 8.5 
7%/ 5.6 7%/ 6.5 7%/ 7.5 7%/ 8.5 
8%/ 5.6 8%/ 6.5 8%/ 7.5 8%/ 8.5 
9%/ 5.6 9%/ 6.5 9%/ 7.5 9%/ 8.5 
10%/ 5.6 10%/ 6.5 10%/ 7.5 10%/ 8.5 
11%/ 5.6 11%/ 6.5 11%/ 7.5 11%/ 8.5 
12%/ 5.6 12%/ 6.5 12%/ 7.5 12%/ 8.5 
13%/ 5.6 13%/ 6.5 13%/ 7.5 13%/ 8.5 
14%/ 5.6 14%/ 6.5 14%/ 7.5 14%/ 8.5 
15%/ 5.6 15%/ 6.5 15%/ 7.5 15%/ 8.5 
16%/ 5.6 16%/ 6.5 16%/ 7.5 16%/ 8.5 
17%/ 5.6 17%/ 6.5 17%/ 7.5 17%/ 8.5 
Conditions: 481- 528  Precipitant: PEG 2000 Salt: Magnesium acetate 0.2M 
PEG / pH pH 5.6 – 8.5 
 
 
 
 
PEG 2000 
6 – 17 % 
(w/v) 
6%/ 5.6 6%/ 6.5 6%/ 7.5 6%/ 8.5 
7%/ 5.6 7%/ 6.5 7%/ 7.5 7%/ 8.5 
8%/ 5.6 8%/ 6.5 8%/ 7.5 8%/ 8.5 
9%/ 5.6 9%/ 6.5 9%/ 7.5 9%/ 8.5 
10%/ 5.6 10%/ 6.5 10%/ 7.5 10%/ 8.5 
11%/ 5.6 11%/ 6.5 11%/ 7.5 11%/ 8.5 
12%/ 5.6 12%/ 6.5 12%/ 7.5 12%/ 8.5 
13%/ 5.6 13%/ 6.5 13%/ 7.5 13%/ 8.5 
14%/ 5.6 14%/ 6.5 14%/ 7.5 14%/ 8.5 
15%/ 5.6 15%/ 6.5 15%/ 7.5 15%/ 8.5 
16%/ 5.6 16%/ 6.5 16%/ 7.5 16%/ 8.5 
17%/ 5.6 17%/ 6.5 17%/ 7.5 17%/ 8.5 
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Conditions: 529- 576     Precipitant: PEG 4000      Salt: Magnesium acetate 0.2M 
PEG / pH pH 5.6 – 8.5 
 
 
 
 
PEG 4000 
6 – 17 % 
(w/v) 
6%/ 5.6 6%/ 6.5 6%/ 7.5 6%/ 8.5 
7%/ 5.6 7%/ 6.5 7%/ 7.5 7%/ 8.5 
8%/ 5.6 8%/ 6.5 8%/ 7.5 8%/ 8.5 
9%/ 5.6 9%/ 6.5 9%/ 7.5 9%/ 8.5 
10%/ 5.6 10%/ 6.5 10%/ 7.5 10%/ 8.5 
11%/ 5.6 11%/ 6.5 11%/ 7.5 11%/ 8.5 
12%/ 5.6 12%/ 6.5 12%/ 7.5 12%/ 8.5 
13%/ 5.6 13%/ 6.5 13%/ 7.5 13%/ 8.5 
14%/ 5.6 14%/ 6.5 14%/ 7.5 14%/ 8.5 
15%/ 5.6 15%/ 6.5 15%/ 7.5 15%/ 8.5 
16%/ 5.6 16%/ 6.5 16%/ 7.5 16%/ 8.5 
17%/ 5.6 17%/ 6.5 17%/ 7.5 17%/ 8.5 
Conditions: 577- 624    Precipitant: PEG 2000      Salt: Potassium chloride 0.2M 
PEG / pH pH 5.6 – 8.5 
 
 
 
 
PEG 2000 
6 – 17 % 
(w/v) 
6%/ 5.6 6%/ 6.5 6%/ 7.5 6%/ 8.5 
7%/ 5.6 7%/ 6.5 7%/ 7.5 7%/ 8.5 
8%/ 5.6 8%/ 6.5 8%/ 7.5 8%/ 8.5 
9%/ 5.6 9%/ 6.5 9%/ 7.5 9%/ 8.5 
10%/ 5.6 10%/ 6.5 10%/ 7.5 10%/ 8.5 
11%/ 5.6 11%/ 6.5 11%/ 7.5 11%/ 8.5 
12%/ 5.6 12%/ 6.5 12%/ 7.5 12%/ 8.5 
13%/ 5.6 13%/ 6.5 13%/ 7.5 13%/ 8.5 
14%/ 5.6 14%/ 6.5 14%/ 7.5 14%/ 8.5 
15%/ 5.6 15%/ 6.5 15%/ 7.5 15%/ 8.5 
16%/ 5.6 16%/ 6.5 16%/ 7.5 16%/ 8.5 
17%/ 5.6 17%/ 6.5 17%/ 7.5 17%/ 8.5 
Conditions: 625- 672  Precipitant: PEG 4000 Salt: Potassium chloride 0.2M 
PEG /pH pH 5.6 – 8.5 
 
 
 
 
PEG 4000 
6 – 17 % 
(w/v) 
6%/ 5.6 6%/ 6.5 6%/ 7.5 6%/ 8.5 
7%/ 5.6 7%/ 6.5 7%/ 7.5 7%/ 8.5 
8%/ 5.6 8%/ 6.5 8%/ 7.5 8%/ 8.5 
9%/ 5.6 9%/ 6.5 9%/ 7.5 9%/ 8.5 
10%/ 5.6 10%/ 6.5 10%/ 7.5 10%/ 8.5 
11%/ 5.6 11%/ 6.5 11%/ 7.5 11%/ 8.5 
12%/ 5.6 12%/ 6.5 12%/ 7.5 12%/ 8.5 
13%/ 5.6 13%/ 6.5 13%/ 7.5 13%/ 8.5 
14%/ 5.6 14%/ 6.5 14%/ 7.5 14%/ 8.5 
15%/ 5.6 15%/ 6.5 15%/ 7.5 15%/ 8.5 
16%/ 5.6 16%/ 6.5 16%/ 7.5 16%/ 8.5 
17%/ 5.6 17%/ 6.5 17%/ 7.5 17%/ 8.5 
FCUP 
Biochemical studies of a membrane protein: The KtrAB ion transporter 
61 
 
 
 
SB screen composition: 
 
 
 
 
 
Table 15 - SB Crystallization Screen Composition. 
 
Conditions: 1-24               Precipitant: PEG400        Salt: Ammonium sulphate 0.2M 
PEG / pH pH 4.6 – 9.5 
 
PEG 400 
15 – 30 % 
(v/v) 
15%/ 4.6 15%/ 5.5 15%/ 6.5 15%/ 7.5 15%/ 8.5 15%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
25%/ 4.6 25%/ 5.5 25%/ 6.5 25%/ 7.5 25%/ 8.5 25%/ 9.5 
30%/ 4.6 30%/ 5.5 30%/ 6.5 30%/ 7.5 30%/ 8.5 30%/ 9.5 
Conditions: 25-48               Precipitant: PEG4000        Salt: Ammonium sulphate 0.2M 
PEG / pH pH 4.6 – 9.5 
 
PEG 4000 
2 – 20 % 
(w/v) 
2%/ 4.6 2%/ 5.5 2%/ 6.5 2%/ 7.5 2%/ 8.5 2%/ 9.5 
5%/ 4.6 5%/ 5.5 5%/ 6.5 5%/ 7.5 5%/ 8.5 5%/ 9.5 
10%/ 4.6 10%/ 5.5 10%/ 6.5 10%/ 7.5 10%/ 8.5 10%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
Conditions: 49-72               Precipitant: PEG400        Salt: Calcium chloride 0.2M 
PEG / pH pH 4.6 – 9.5 
 
PEG 400 
15 – 30 % 
(v/v) 
15%/ 4.6 15%/ 5.5 15%/ 6.5 15%/ 7.5 15%/ 8.5 15%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
25%/ 4.6 25%/ 5.5 25%/ 6.5 25%/ 7.5 25%/ 8.5 25%/ 9.5 
30%/ 4.6 30%/ 5.5 30%/ 6.5 30%/ 7.5 30%/ 8.5 30%/ 9.5 
Conditions: 73-96               Precipitant: PEG4000        Salt: Calcium chloride 0.2M 
PEG / pH pH 4.6 – 9.5 
 
PEG 4000 
2 – 20 % 
(w/v) 
2%/ 4.6 2%/ 5.5 2%/ 6.5 2%/ 7.5 2%/ 8.5 2%/ 9.5 
5%/ 4.6 5%/ 5.5 5%/ 6.5 5%/ 7.5 5%/ 8.5 5%/ 9.5 
10%/ 4.6 10%/ 5.5 10%/ 6.5 10%/ 7.5 10%/ 8.5 10%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
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Conditions: 97-120        Precipitant: PEG400        Salt: Lithium-sodium sulphate 0.2M 
PEG / pH pH 4.6 – 9.5 
 
PEG 400 
15 – 30 % 
(v/v) 
15%/ 4.6 15%/ 5.5 15%/ 6.5 15%/ 7.5 15%/ 8.5 15%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
25%/ 4.6 25%/ 5.5 25%/ 6.5 25%/ 7.5 25%/ 8.5 25%/ 9.5 
30%/ 4.6 30%/ 5.5 30%/ 6.5 30%/ 7.5 30%/ 8.5 30%/ 9.5 
Conditions: 121-144       Precipitant: PEG4000        Salt: Lithium-sodium sulphate 0.2M 
PEG /pH pH 4.6 – 9.5 
 
PEG 4000 
2 – 20 % 
(w/v) 
2%/ 4.6 2%/ 5.5 2%/ 6.5 2%/ 7.5 2%/ 8.5 2%/ 9.5 
5%/ 4.6 5%/ 5.5 5%/ 6.5 5%/ 7.5 5%/ 8.5 5%/ 9.5 
10%/ 4.6 10%/ 5.5 10%/ 6.5 10%/ 7.5 10%/ 8.5 10%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
Conditions: 145-168              Precipitant: PEG400        Salt: Ammonium formate 1M 
PEG / pH pH 4.6 – 9.5 
 
PEG 400 
15 – 30 % 
(v/v) 
15%/ 4.6 15%/ 5.5 15%/ 6.5 15%/ 7.5 15%/ 8.5 15%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
25%/ 4.6 25%/ 5.5 25%/ 6.5 25%/ 7.5 25%/ 8.5 25%/ 9.5 
30%/ 4.6 30%/ 5.5 30%/ 6.5 30%/ 7.5 30%/ 8.5 30%/ 9.5 
Conditions: 169-192             Precipitant: PEG4000        Salt: Ammonium formate 1M 
PEG / pH pH 4.6 – 9.5 
 
PEG 4000 
2 – 20 % 
(w/v) 
2%/ 4.6 2%/ 5.5 2%/ 6.5 2%/ 7.5 2%/ 8.5 2%/ 9.5 
5%/ 4.6 5%/ 5.5 5%/ 6.5 5%/ 7.5 5%/ 8.5 5%/ 9.5 
10%/ 4.6 10%/ 5.5 10%/ 6.5 10%/ 7.5 10%/ 8.5 10%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
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Conditions: 193-216            Precipitant: PEG400        Salt: Magnesium acetate 0.05M 
PEG / pH pH 4.6 – 9.5 
 
PEG 400 
15 – 30 % 
(v/v) 
15%/ 4.6 15%/ 5.5 15%/ 6.5 15%/ 7.5 15%/ 8.5 15%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
25%/ 4.6 25%/ 5.5 25%/ 6.5 25%/ 7.5 25%/ 8.5 25%/ 9.5 
30%/ 4.6 30%/ 5.5 30%/ 6.5 30%/ 7.5 30%/ 8.5 30%/ 9.5 
Conditions: 217-240             Precipitant: PEG4000        Salt: Magnesium acetate 0.05M 
PEG / pH pH 4.6 – 9.5 
 
PEG 4000 
2 – 20 % 
(w/v) 
2%/ 4.6 2%/ 5.5 2%/ 6.5 2%/ 7.5 2%/ 8.5 2%/ 9.5 
5%/ 4.6 5%/ 5.5 5%/ 6.5 5%/ 7.5 5%/ 8.5 5%/ 9.5 
10%/ 4.6 10%/ 5.5 10%/ 6.5 10%/ 7.5 10%/ 8.5 10%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
Conditions: 241-264            Precipitant: PEG400        Salt: Sodium chloride 1M 
PEG / pH pH 4.6 – 9.5 
 
PEG 400 
15 – 30 % 
(v/v) 
15%/ 4.6 15%/ 5.5 15%/ 6.5 15%/ 7.5 15%/ 8.5 15%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
25%/ 4.6 25%/ 5.5 25%/ 6.5 25%/ 7.5 25%/ 8.5 25%/ 9.5 
30%/ 4.6 30%/ 5.5 30%/ 6.5 30%/ 7.5 30%/ 8.5 30%/ 9.5 
Conditions: 265-288             Precipitant: PEG4000        Salt: Sodium chloride 1M 
PEG / pH pH 4.6 – 9.5 
 
PEG 4000 
2 – 20 % 
(w/v) 
2%/ 4.6 2%/ 5.5 2%/ 6.5 2%/ 7.5 2%/ 8.5 2%/ 9.5 
5%/ 4.6 5%/ 5.5 5%/ 6.5 5%/ 7.5 5%/ 8.5 5%/ 9.5 
10%/ 4.6 10%/ 5.5 10%/ 6.5 10%/ 7.5 10%/ 8.5 10%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
 
 
 
 
 
Conditions: 289-312            Precipitant: PEG400        Salt: Potassium phosphate 0.2M 
PEG / pH pH 4.6 – 9.5 
 
PEG 400 
15 – 30 % 
(v/v) 
15%/ 4.6 15%/ 5.5 15%/ 6.5 15%/ 7.5 15%/ 8.5 15%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
25%/ 4.6 25%/ 5.5 25%/ 6.5 25%/ 7.5 25%/ 8.5 25%/ 9.5 
30%/ 4.6 30%/ 5.5 30%/ 6.5 30%/ 7.5 30%/ 8.5 30%/ 9.5 
Conditions: 313-336             Precipitant: PEG4000        Salt: Potassium phosphate 0.2M 
PEG / pH pH 4.6 – 9.5 
 
PEG 4000 
2 – 20 % 
(w/v) 
2%/ 4.6 2%/ 5.5 2%/ 6.5 2%/ 7.5 2%/ 8.5 2%/ 9.5 
5%/ 4.6 5%/ 5.5 5%/ 6.5 5%/ 7.5 5%/ 8.5 5%/ 9.5 
10%/ 4.6 10%/ 5.5 10%/ 6.5 10%/ 7.5 10%/ 8.5 10%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
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Conditions: 337-360            Precipitant: PEG400        Salt: Potassium chloride 0.5M 
PEG / pH pH 4.6 – 9.5 
 
PEG 400 
15 – 30 % 
(v/v) 
15%/ 4.6 15%/ 5.5 15%/ 6.5 15%/ 7.5 15%/ 8.5 15%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
25%/ 4.6 25%/ 5.5 25%/ 6.5 25%/ 7.5 25%/ 8.5 25%/ 9.5 
30%/ 4.6 30%/ 5.5 30%/ 6.5 30%/ 7.5 30%/ 8.5 30%/ 9.5 
Conditions: 361-384           Precipitant: PEG4000        Salt: Potassium chloride 0.5M 
PEG / pH pH 4.6 – 9.5 
 
PEG 4000 
2 – 20 % 
(w/v) 
2%/ 4.6 2%/ 5.5 2%/ 6.5 2%/ 7.5 2%/ 8.5 2%/ 9.5 
5%/ 4.6 5%/ 5.5 5%/ 6.5 5%/ 7.5 5%/ 8.5 5%/ 9.5 
10%/ 4.6 10%/ 5.5 10%/ 6.5 10%/ 7.5 10%/ 8.5 10%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
Conditions: 385-408            Precipitant: PEG400        Salt: No salt 
PEG / pH pH 4.6 – 9.5 
 
PEG 400 
15 – 30 % 
(v/v) 
15%/ 4.6 15%/ 5.5 15%/ 6.5 15%/ 7.5 15%/ 8.5 15%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
25%/ 4.6 25%/ 5.5 25%/ 6.5 25%/ 7.5 25%/ 8.5 25%/ 9.5 
30%/ 4.6 30%/ 5.5 30%/ 6.5 30%/ 7.5 30%/ 8.5 30%/ 9.5 
Conditions: 409-432           Precipitant: PEG4000        Salt: No salt 
PEG / pH pH 4.6 – 9.5 
 
PEG 4000 
2 – 20 % 
(w/v) 
2%/ 4.6 2%/ 5.5 2%/ 6.5 2%/ 7.5 2%/ 8.5 2%/ 9.5 
5%/ 4.6 5%/ 5.5 5%/ 6.5 5%/ 7.5 5%/ 8.5 5%/ 9.5 
10%/ 4.6 10%/ 5.5 10%/ 6.5 10%/ 7.5 10%/ 8.5 10%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
Conditions: 433-456               Precipitant: PEG400        Salt: Potassium-sodium tartrate 0.2M 
PEG / pH pH 4.6 – 9.5 
 
PEG 400 
15 – 30 % 
(v/v) 
15%/ 4.6 15%/ 5.5 15%/ 6.5 15%/ 7.5 15%/ 8.5 15%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
25%/ 4.6 25%/ 5.5 25%/ 6.5 25%/ 7.5 25%/ 8.5 25%/ 9.5 
30%/ 4.6 30%/ 5.5 30%/ 6.5 30%/ 7.5 30%/ 8.5 30%/ 9.5 
Conditions: 453-480              Precipitant: PEG4000        Salt: Potassium-sodium tartrate 0.2M 
PEG / pH pH 4.6 – 9.5 
 
PEG 4000 
2 – 20 % 
(w/v) 
2%/ 4.6 2%/ 5.5 2%/ 6.5 2%/ 7.5 2%/ 8.5 2%/ 9.5 
5%/ 4.6 5%/ 5.5 5%/ 6.5 5%/ 7.5 5%/ 8.5 5%/ 9.5 
10%/ 4.6 10%/ 5.5 10%/ 6.5 10%/ 7.5 10%/ 8.5 10%/ 9.5 
20%/ 4.6 20%/ 5.5 20%/ 6.5 20%/ 7.5 20%/ 8.5 20%/ 9.5 
